

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: JANA HINES Examiner #: \_\_\_\_\_ Date: 9/14/80  
 Art Unit: 1645 Phone Number 305-0481 Serial Number: 091-164-112  
 Mail Box and Bldg/Room Location: CHI 1217 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Assay for Carbohydrate-Free transferrin  
 Inventors (please provide full names): ERLING SUNDRE HAGED

Earliest Priority Filing Date: 06/1977

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

siderophilin alcoholism latechol-consumption  
transferrin Dis. 716.124.50.800 Dis. 716.157.890 Dis. 716.556.901  
carbohydrate free transferrin (CDT) Dis. 716.372.715.18287 Dis. 716.124.790.223.83  
asialo, monosialo, trisialo, tetrasialo, pentasialo  
disialo transferrin  
carbohydrate deficient transferrin

Point of Contact:

Mary Hale

Technical Info. Specialist  
 CM1 12D16 Tel: 308-4258

alcohol<sup>(a)</sup> drinking 21.739.100.250  
F1.145.317.269 F3.900.100.350  
alcoholism  
temperance? drug dependence  
alcohol consumption

*Please search the claims and inventor*  
*Thanks*  
 1049  
 1024-34  
 44

## STAFF USE ONLY

Type of Search		Vendors and cost where applicable
Searcher: <u>Wiley</u>	NA Sequence (#) _____	STN <u>308.56</u>
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic <input checked="" type="checkbox"/>	Dr.Link _____
Date Completed: <u>9/13</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>6</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>25</u>	Other _____	Other (specify) _____

J. HINES  
464158

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 10:24:17 ON 13 SEP 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 12 SEP 2000 HIGHEST RN 288839-14-5

DICTIONARY FILE UPDATES: 12 SEP 2000 HIGHEST RN 288839-14-5

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=> e transferrin/cn 5

E1	1	TRANSFERCAT/CN
E2	1	TRANSFERIN KW/CN
E3	0 -->	TRANSFERRIN/CN
E4	1	TRANSFERRIN (206-GLUTAMINE) (HUMAN)/CN
E5	1	TRANSFERRIN (207-GLUTAMIC ACID) (HUMAN)/CN

=> e carbohydrate free transferrin/cn 5

E1	1	CARBOHYDRASE/CN
E2	1	CARBOHYDRATASE/CN
E3	0 -->	CARBOHYDRATE FREE TRANSFERRIN/CN
E4	1	CARBOHYDRATE ISOMERASE, KPSF/GUTQ FAMILY (CHLAMYDIA MURIDARU M STRAIN NIGG GENE TC0679)/CN
E5	1	CARBOHYDRATE ISOMERASE, KPSF/GUTQ FAMILY (CHLAMYDOPHILA PNEU MONIAE AR39 STRAIN AR39 GENE CP0226)/CN

=> s ?transferrin?/cns

L1 443 ?TRANSFERRIN?/CNS

=> fil medl,caplus,biosis,embase,wpids,jicst

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.20

4.35

FILE 'MEDLINE' ENTERED AT 10:25:24 ON 13 SEP 2000

FILE 'CAPLUS' ENTERED AT 10:25:24 ON 13 SEP 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Prepared by M. Hale 308-4258

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:25:24 ON 13 SEP 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 10:25:24 ON 13 SEP 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:25:24 ON 13 SEP 2000  
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 10:25:24 ON 13 SEP 2000  
COPYRIGHT (C) 2000 Japan Science and Technology Corporation (JST)

=> s (l1 or ?transferrin? or siderophilin? or (d12.775.124.50.800 or  
d12.776.157.890 or d12.776.377.715.192.839 or d12.776.556.901/ct) and  
(alcoholism or alcohol(2a)(consump? or drink?) or temperance or drug  
dependence or (f1.145.317.269 or c21.739.100.250 or f3.900.100.350)/ct)

UNMATCHED LEFT PARENTHESIS '(L1'  
The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s (l1 or ?transferrin? or siderophilin? or (d12.775.124.50.800 or  
d12.776.157.890 or d12.776.377.715.192.839 or d12.776.556.901/ct)) and  
(alcoholism or alcohol(2a)(consump? or drink?) or temperance or drug  
dependence or (f1.145.317.269 or c21.739.100.250 or f3.900.100.350)/ct)

L2 411 FILE MEDLINE  
L3 208 FILE CAPLUS  
L4 331 FILE BIOSIS  
L5 427 FILE EMBASE  
LEFT TRUNCATION IGNORED FOR '?TRANSFERRIN?' FOR FILE 'WPIDS'  
L6 15 FILE WPIDS  
LEFT TRUNCATION IGNORED FOR '?TRANSFERRIN?' FOR FILE 'JICST-EPLUS'  
L7 4 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L8 1396 (L1 OR ?TRANSFERRIN? OR SIDEROPHILIN? OR (D12.775.124.50.800  
OR  
D12.776.157.890 OR D12.776.377.715.192.839 OR  
D12.776.556.901/CT  
) ) AND (ALCOHOLISM OR ALCOHOL(2A)(CONSUMP? OR DRINK?) OR  
TEMPERA  
NCE OR DRUG DEPENDENCE OR (F1.145.317.269 OR C21.739.100.250  
OR  
F3.900.100.350)/CT)

Left truncation is not valid in the specified search field in the  
specified file. The term has been searched without left truncation.  
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'  
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you  
used a truncation symbol after a punctuation mark, the system may  
interpret the truncation symbol as being at the beginning of a term.  
Prepared by M. Hale 308-4258

Implied proximity is used in search fields indexed as single words,  
for example, the Basic Index.

=> s l8(10a)carbohydrate free

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L2(10A)CARBOHYDRA'

L9 0 FILE MEDLINE

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L3(10A)CARBOHYDRA'

L10 2 FILE CAPLUS

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L4(10A)CARBOHYDRA'

L11 0 FILE BIOSIS

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L5(10A)CARBOHYDRA'

L12 0 FILE EMBASE

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L6(10A)CARBOHYDRA'

L13 2 FILE WPIDS

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L7(10A)CARBOHYDRA'

L14 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L15 4 L8(10A) CARBOHYDRATE FREE

=> dup rem l15

PROCESSING COMPLETED FOR L15

L16 2 DUP REM L15 (2 DUPLICATES REMOVED)

=> d cbib abs 1-2 hit

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 1

2000:421411 Document No. 133:40212 Dipstick for **carbohydrate-**

**free transferrin** assay. Sundrehagen, Erling

(Axis-Shield Asa, Norway; Dzieglewska, Hanna). PCT Int. Appl. WO

2000036418 A1 20000622, 50 pp. DESIGNATED STATES: W: AE, AL, AM, AT,

AT,

AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English).

CODEN: PIXXD2. APPLICATION: WO 1999-GB4191 19991210. PRIORITY: GB 1998-27411 19981211.

AB The invention relates to a new dipstick assay for detecting and quantifying the content of an analyte in a sample. The assay is particularly useful for example in the diagnosis and monitoring of **alcoholism** by the detection of asialo **transferrin** or **carbohydrate free transferrin** (CFT). Thus,

provided is a dipstick for detg. the content of a target analyte variant

Prepared by M. Hale 308-4258

Page 3

in a mixt. of analyte variants in a sample, comprising: (a) a sample application zone, (b) a screening zone having an immobilized binding ligand having a binding affinity for a non-target analyte variant or variants, (c) a conjugate zone comprising a detector reagent, (d) a reading zone for detection of said analyte. A dipstick for detn. of CFT in serum had a zone of immobilized Sambuccus nigra lectin and ConA above the sample application zone, a detector reagent zone with anti-**transferrin** antibody labeled with blue latex particles, and a reading zone contg. immobilized anti-**transferrin** antibodies. An adsorbent sink pad was at the far end of the dipstick.

TI Dipstick for **carbohydrate-free transferrin** assay

AB The invention relates to a new dipstick assay for detecting and quantifying the content of an analyte in a sample. The assay is particularly useful for example in the diagnosis and monitoring of **alcoholism** by the detection of asialo **transferrin** or **carbohydrate free transferrin** (CFT). Thus, provided is a dipstick for detg. the content of a target analyte variant in a mixt. of analyte variants in a sample, comprising: (a) a sample application zone, (b) a screening zone having an immobilized binding ligand having a binding affinity for a non-target analyte variant or variants, (c) a conjugate zone comprising a detector reagent, (d) a reading zone for detection of said analyte. A dipstick for detn. of CFT in serum had a zone of immobilized Sambuccus nigra lectin and ConA above the sample application zone, a detector reagent zone with anti-**transferrin** antibody labeled with blue latex particles, and a reading zone contg. immobilized anti-**transferrin** antibodies. An adsorbent sink pad was at the far end of the dipstick.

ST dipstick **carbohydrate free transferrin**;  
asialo **transferrin** detection dipstick **alcoholism**

IT **Transferrins**

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(CDT (carbohydrate-deficient **transferrin**); dipstick for **carbohydrate-free transferrin** assay)

IT **Transferrins**

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(asialo**transferrins**; dipstick for **carbohydrate-free transferrin** assay)

IT Ligands

RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(conjugated, with labels, as detector reagents; dipstick for **carbohydrate-free transferrin** assay)

IT Latex

(detector reagent contg. colored particle of, as labels; dipstick for **carbohydrate-free transferrin** assay)

IT Particles

(detector reagent contg., as labels; dipstick for **carbohydrate-free transferrin** assay)

IT Affinity

Blood analysis

Body fluid

Urine analysis

(dipstick for **carbohydrate-free transferrin** assay)

IT Reagents  
 RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (dipstick for **carbohydrate-free transferrin** assay)

IT Carbohydrates, biological studies  
 RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)  
 (dipstick for **carbohydrate-free transferrin** assay)

IT Analytical apparatus  
 (dipstick; dipstick for **carbohydrate-free transferrin** assay)

IT **Transferrins**  
 RL: ARU (Analytical role, unclassified); REM (Removal or disposal); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (disialo- or monosialo-, removal of; dipstick for **carbohydrate-free transferrin** assay)

IT Immunoglobulins  
 RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (fragments, to **transferrin**, labeled; dipstick for **carbohydrate-free transferrin** assay)

IT Ligands  
 RL: ARU (Analytical role, unclassified); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (immobilized, binding to nontarget analyte variant; dipstick for **carbohydrate-free transferrin** assay)

IT Antibodies  
 RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (immobilized; dipstick for **carbohydrate-free transferrin** assay)

IT Antibodies  
 RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (labeled, to **transferrin**; dipstick for **carbohydrate-free transferrin** assay)

IT Sialic acids  
 RL: ARU (Analytical role, unclassified); REM (Removal or disposal); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (lectin in screening zone binding to; dipstick for **carbohydrate-free transferrin** assay)

IT Oligosaccharides, analysis  
 RL: ARU (Analytical role, unclassified); REM (Removal or disposal); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

- (ligand in screening zone binding to; dipstick for **carbohydrate-free transferrin** assay)
- IT **Alcoholism**  
(monitoring of; dipstick for **carbohydrate-free transferrin** assay)
- IT Agglutinins and Lectins  
RL: ARU (Analytical role, unclassified); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(of Sambuccus nigra, immobilized; dipstick for **carbohydrate-free transferrin** assay)
- IT Agglutinins and Lectins  
RL: ARU (Analytical role, unclassified); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(sialic acid-binding, in screening zone; dipstick for **carbohydrate-free transferrin** assay)
- IT 64-17-5, Ethanol, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
(assessment of consumption of; dipstick for **carbohydrate-free transferrin** assay)
- IT 7440-57-5, Gold, biological studies  
RL: ARG (Analytical reagent use); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(colloid particles, as label; dipstick for **carbohydrate-free transferrin** assay)
- IT 11028-71-0D, ConA, immobilized  
RL: ARU (Analytical role, unclassified); DEV (Device component use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(dipstick for **carbohydrate-free transferrin** assay)

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 2

1999:42622 Document No. 130:91547 Assay for **carbohydrate-free transferrin**. Sundrehagen, Erling (Axis Biochemicals/Asa, Norway; Dzieglewska, Hanna, E.). PCT Int. Appl. WO 9900672 A1 19990107, 39 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1998-GB1875 19980626. PRIORITY: GB 1997-13559 19970626.

AB The present invention provides a method for the detn. of **carbohydrate-free transferrin** in a body fluid for use in the assessment of **alc. consumption**, said method comprising (a) contacting a sample of said body fluid with a carbohydrate-binding ligand, to bind any carbohydrate or carbohydrate-contg. moieties in said sample to said ligand; (b) sepg. a fraction not binding to said ligand and (c) detg. the content of **transferrin** in said fraction. Also provided are kits for carrying

out such a method.

TI Assay for **carbohydrate-free transferrin**

AB The present invention provides a method for the detn. of **carbohydrate-free transferrin** in a body fluid for use in the assessment of **alc. consumption**, said method comprising (a) contacting a sample of said body fluid with a carbohydrate-binding ligand, to bind any carbohydrate or carbohydrate-contg. moieties in said sample to said ligand; (b) sepg. a fraction not binding to said ligand and (c) detg. the content of **transferrin** in said fraction. Also provided are kits for carrying out such a method.

ST **alcoholism** diagnosis **carbohydrate free transferrin** detn blood

IT **Transferrins**

RL: ANT (Analyte); BOC (Biological occurrence); BPR (Biological process); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)  
(CDT (carbohydrate-deficient **transferrin**); assay for **carbohydrate-free transferrin** as indicator of alcoholism)

IT **Transferrins**

RL: ANT (Analyte); BOC (Biological occurrence); BPR (Biological process); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)  
(CFT (**carbohydrate-free transferrin**); assay for **carbohydrate-free transferrin** as indicator of alcoholism)

IT **Alcoholism**

Blood  
Blood analysis  
Body fluid  
Castor bean  
Centrifugation  
Chromatography  
Diagnosis  
Elder (*Sambucus nigra*)  
Elder (*Sambucus sieboldiana*)  
Escherichia coli  
Filtration  
Helicobacter pylori  
Immobilization (molecular)  
Ion exchange  
Liquid chromatography  
Maackia amurensis  
Nephelometry  
Opacifiers  
Precipitation (chemical)  
Serum (blood)  
Sunn hemp (*Crotalaria juncea*)  
Test kits  
Turbidimetry  
Wheat germ  
(assay for **carbohydrate-free transferrin** as indicator of alcoholism)

IT **Sialic acids**

RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BPR  
Prepared by M. Hale 308-4258 Page 7



(Biological process); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PROC (Process)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT Agglutinins  
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT Antibodies  
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT Lectins  
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT Ligands  
 Proteins (specific proteins and subclasses)  
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (carbohydrate-binding; assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT Immunoassay  
 (turbidimetric; assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT 64-17-5, Ethanol, biological studies  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

IT 11028-71-0, Concanavalin A  
 RL: ARU (Analytical role, unclassified); BPR (Biological process); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)  
 (assay for **carbohydrate-free transferrin** as indicator of **alcoholism**)

=> s 18(10a)carbohydrate deficien?

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L2(10A)CARBOHYDRA'  
 L17 260 FILE MEDLINE  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L3(10A)CARBOHYDRA'  
 L18 145 FILE CAPLUS  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L4(10A)CARBOHYDRA'  
 L19 245 FILE BIOSIS

Prepared by M. Hale 308-4258

Page 8

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L5(10A)CARBOHYDRA'  
 L20 251 FILE EMBASE  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L6(10A)CARBOHYDRA'  
 L21 6 FILE WPIDS  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'L7(10A)CARBOHYDRA'  
 L22 1 FILE JICST-EPLUS

TOTAL FOR ALL FILES  
 L23 908 L8(10A) CARBOHYDRATE DEFICIEN?

=> s (carbohydrate(w)(free or deficient?))(5a)(l1 or ?transferrin? or  
 siderophilin? or (d12.775.124.50.800 or d12.776.157.890 or  
 d12.776.377.715.192.839 or d12.776.556.901 or d12.776.124.790.223.839)/ct)

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EFICIEN?))(5A)(L1'  
 L24 376 FILE MEDLINE  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EFICIEN?))(5A)(L1'  
 L25 236 FILE CAPLUS  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EFICIEN?))(5A)(L1'  
 L26 459 FILE BIOSIS  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EFICIEN?))(5A)(L1'  
 L27 382 FILE EMBASE  
 LEFT TRUNCATION IGNORED FOR '?TRANSFERRIN?' FOR FILE 'WPIDS'  
 L28 8 FILE WPIDS  
 LEFT TRUNCATION IGNORED FOR '?TRANSFERRIN?' FOR FILE 'JICST-EPLUS'  
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
 FIELD CODE - 'AND' OPERATOR ASSUMED 'EFICIEN?))(5A)(L1'  
 L29 25 FILE JICST-EPLUS

TOTAL FOR ALL FILES  
 L30 1486 (CARBOHYDRATE(W)(FREE OR DEFICIEN?))(5A)(L1 OR ?TRANSFERRIN?  
 OR  
 D12.7 76.377.715.192.839 OR D12.776.157.890 OR  
 D12.776.124.790.223.839  
 )/CT)

The search profile entered contains terms joined by a proximity operator which does not work in the specified field. Some proximity operators work in specific fields. For example, an expression such as 'OLEFINS/CS(L)REACTIONS/CS' cannot be searched as entered if the (L) operator does not apply to the CS field. In such cases, the system does the search in the field you have specified, but changes the proximity operator to 'AND' logic.

To look at the terms, operations, etc., in an L#, enter "DISPLAY QUERY" followed by the L# at an arrow prompt (=>). To see this information for a saved query, enter "ACTIVATE" and the query name, followed by '/Q' at an arrow prompt.

Prepared by M. Hale 308-4258

=> s l30(10a)(alcoholism or alcohol(2a)(consump? or drink?) or temperance or drug dependence or (f1.145.317.269 or c21.739.100.250 or f3.900.100.350)/ct)

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L24(10A)(ALCOHOLIS'  
L31 260 FILE MEDLINE  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L25(10A)(ALCOHOLIS'  
L32 145 FILE CAPLUS  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L26(10A)(ALCOHOLIS'  
L33 245 FILE BIOSIS  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L27(10A)(ALCOHOLIS'  
L34 251 FILE EMBASE  
L35 3 FILE WPIDS  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L29(10A)(ALCOHOLIS'  
L36 1 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L37 905 L30(10A)(ALCOHOLISM OR ALCOHOL(2A)(CONSUMP? OR DRINK?) OR  
TEMPERANCE OR DRUG DEPENDENCE OR (F1.145.317.269 OR C21.739.100.250  
OR F3.900.100.350)/CT)

=> s l37 and (asialo or monosialo or trisialo or tetrasialo or pentasialo or disialo)

L38 8 FILE MEDLINE  
L39 14 FILE CAPLUS  
L40 7 FILE BIOSIS  
L41 6 FILE EMBASE  
L42 0 FILE WPIDS  
L43 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L44 35 L37 AND (ASIALO OR MONOSIALO OR TRISIALO OR TETRASIALO OR  
PENTASIALO OR DISIALO)

=> s l44 not l15

L45 8 FILE MEDLINE  
L46 13 FILE CAPLUS  
L47 7 FILE BIOSIS  
L48 6 FILE EMBASE  
L49 0 FILE WPIDS  
L50 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L51 34 L44 NOT L15

=> dup rem l51

PROCESSING COMPLETED FOR L51

L52 15 DUP REM L51 (19 DUPLICATES REMOVED)

=> d cbib abs 1-15

L52 ANSWER 1 OF 15 MEDLINE

DUPLICATE 1

2000403130 Document Number: 20387106. Does **trisialo-transferrin** provide valuable information for the laboratory diagnosis of chronically increased **alcohol consumption** by determination of **carbohydrate-deficient transferrin**?. Dibbelt L. (Institute of Clinical Chemistry, Medical University, D-23538 Luebeck, Germany. ) CLINICAL CHEMISTRY, (2000 Aug) 46 (8 Pt 1) 1203-5. Journal code: DBZ. ISSN: 0009-9147. Pub. country:

United

States. Language: English.

L52 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2000 ACS

DUPLICATE 2

2000:395294 Document No. 133:130888 Investigation by isoelectric focusing of

the initial **carbohydrate-deficient transferrin** (CDT) and non-CDT **transferrin** isoform fractionation step involved in determination of CDT by the ChronAlcol.D. assay. Hackler, Rolf; Arndt, Torsten; Helwig-Rolig, Angelika; Kropf, Juergen; Steinmetz, Armin; Schaefer, Juergen R. (Zentrum fur Innere Medizin, Abteilung Kardiologie, Philipps-Universitat, Marburg, D-35033, Germany). Clin. Chem. (Washington, D. C.), 46(4), 483-492 (English) 2000. CODEN: CLCHAU. ISSN: 0009-9147. Publisher: American Association for Clinical Chemistry.

AB Background: The introduction of a new set of reagents for the detn. of **carbohydrate-deficient transferrin** (CDT) as a marker of chronic alc. abuse requires an independent evaluation of the analytic specificity of the test. This information is needed for correct interpretation and classification of test results. Methods: Isoelec. focusing on the PhastSystem followed by immunofixation, silver staining, and densitometry was used to validate the initial **transferrin** isoform fractionation step on anion-exchange micro-columns involved in

the

ChronAlcol.D. assay. Results: The in vitro **transferrin** iron load was complete and stable. The CDT and non-CDT **transferrin** fractionation on anion-exchange micro-columns was reliable and reproducible (CV .ltoreq.10%). Except for quant. unimportant traces of **trisialo-Fe2-transferrin** (<5% of total CDT), only **asialo-**, **mono-**, and **disialo-Fe2-transferrin** were detected in the micro-column eluates (n = 170). There was a loss of proportionally similar amts. of **asialo-Fe2-transferrin** (during column rinsing) and **disialo-Fe2-transferrin** (on the anion exchanger). Thus, the peak height ratios for **disialo-** and **asialo-Fe2-transferrin** did not change from >1 (serum) to <1 (eluates) as described for the CDTest assays.

The **transferrin** patterns in the ChronAlcol.D. eluates were representative of those in serum. **Transferrin** D variants with isoelec. points close to that of **trisialo-Fe2-transferrin** C1 did not cause overdtn. of CDT by the ChronAlcol.D. test. Conclusions: The initial CDT and non-CDT fractionation step involved in detn. of CDT by the ChronAlcol.D. assay is efficient for

Prepared by M. Hale 308-4258

Page 11

eliminating non-CDT **transferrins** from serum before quantification of CDT in the final turbidimetric immunoassay. We recommend IEF for validation of other (com.) CDT anal. methods and of odd CDT results.

L52 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2000 ACS

2000:141860 Document No. 132:344172 Improved method for **carbohydrate-deficient transferrin** determination in human serum by capillary zone electrophoresis. Crivellente, F.; Fracasso, G.;

Valentini,

R.; Manetto, G.; Riviera, A. P.; Tagliaro, F. (Institute of Forensic Medicine, University of Verona, Verona, Italy). J. Chromatogr., B: Biomed. Sci. Appl., 739(1), 81-93 (English) 2000. CODEN: JCBBEF. ISSN: 0378-4347. Publisher: Elsevier Science B.V..

AB **Carbohydrate-deficient transferrin** (CDT) is a reliable marker of chronic or repeated alc. abuse. It indicates a group

of isoforms of human **transferrin** (Tf), the main iron transport serum protein, deficient in sialic acid residues (**asialo-**, **monosialo-** and **disialo-**Tf) in comparison to the main **isotransferrin** which contains four sialic acid groups (**tetrasialo-**Tf). The aim of the present work was to develop a capillary electrophoretic method suitable for rapid detn. of CDT components in serum. Serum samples (0.1 mL) were satd. with iron by incubation with 10 mM FeCl<sub>3</sub> (2 .mu.l) and 500 mM NaHCO<sub>3</sub> (3 .mu.l) for 30 min, then dild. 1:10 in water and injected by pos. pressure (0.5 p.s.i. for 10 s). Sepn. was performed with a capillary zone electrophoretic method using bare fused-silica capillaries (57 cm.times.20 .mu.m I.D.)

and

pH a buffer composed of 100 mM sodium tetraborate adjusted with 6 M HCl to

8.3 added with 1.5 mM diaminobutane. Applied voltage was 20 kV and temp. 25.degree.. Detection was by UV absorption at 200 nm wavelength. Under the described conditions, **asialo-**, **monosialo-**, **disialo-**, **trisialo-** and **tetrasialo-transferrin** were baseline sepd. The limit of detection (signal-to-noise ratio of 2) was about 0.3% for **disialo-**Tf, and 0.5% of **trisialo-**Tf, expressed as percentages of the **terasialo-**Tf peak area. Day-to-day RSDs of relative migration times were .ltoreq.0.2%. Quantitation showed day-to-day RSDs .ltoreq.6.9% and .ltoreq.10.9% for **disialo-** and **trisialo-**Tf, resp. The results from 79 control subjects, including social drinkers, and 23 alcoholics showed **disialo-** and **trisialo-**Tf significantly increased in patients (P<0.0001 and <0.01, resp.). A clear interference from **trisialo-**Tf in an immunoassay for CDT was demonstrated. The present method is suitable for confirmation of CDT immunoassays by independent technique.

L52 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2000 ACS

1999:516842 Document No. 131:155457 Experience with the examination of **carbohydrate-deficient transferrin**. Stejskal, David; Vavrouskova, J.; Frankova, M.; Jedelsky, L.; Horalik, D.; Pastorkova, R. (Oddeleni Laboratorni Mediciny, Nemocnice Sternberk, Sternberk, 78516, Czech Rep.). Vnitr. Lek., 45(6), 347-352 (Czech) 1999. CODEN: VNLEAH. ISSN: 0042-773X. Publisher: Ceska Lekarska Spolecnost J. Ev. Purkyne.

AB **Carbohydrate-deficient blood serum transferrin**  
 (CDT) is considered a useful indicator of alc. abuse. There is a no. of methods for the CDT status assessment. The most frequent clin. assessment uses the percentage of CDT in total **transferrin**. We assessed CDT by the Boehringer (CDT-BM) and Sanqui BioTech (CDT-SB) homogeneous immunoanal. in 49 alc. patients, including 16 who admitted alc. abuse >60 g alc. more than 4-times per wk. The %CDT detd. by the CDT-BM method was higher than with the CDT-SB. After classification of the patients into 2 subgroups based on alc. intake the subgroups differed only in the values of CDT-SB and CDT-BM. In the subgroup of patients with alc. abuse we found relations between CDT-MB and indicators of hepatic lesions. CDT-SB showed an assocn. only with the blood aspartate transaminase activity. This may suggest a greater specificity of CDT-SB. The values of .gamma.-glutamyl transferase activity and the mean corpuscular vol. were independent of CDT in subjects with alc. abuse. In patients who negated alc. intake the CDT-SB found a gender difference probably because the CDT-SB method (unlike CDT-BM) detects only **asialo**, **monosialo**, and **disialo** isoforms of **transferrin** and women have higher levels of **monosialo** forms. The CDT-SB method had almost abs. specificity and sensitivity. Compared to the older CDT-BM method, with CDT-SB we did not find any false increases in patients with hepatopathy symptoms or false neg. results. The described methodol. innovation may facilitate differential diagnosis of various diseases.

L52 ANSWER 5 OF 15 MEDLINE

2000247948 Document Number: 20247948. [CDT (desialylated **transferrin**)--a new biochemical marker of alcohol abuse]. CDT (desialowana transferyna)--nowy biochemiczny marker naduzywania alkoholu. Chrostek L; Szmitkowski M. (Zakladu Diagnostyki Biochemicznej AM w Bialymstoku.) PSYCHIATRIA POLSKA, (1999 Mar-Apr) 33 (2) 189-201. Journal code: QBJ. ISSN: 0033-2674. Pub. country: Poland. Language: Polish.

AB Serum concentration of **carbohydrate-deficient transferrin** (CDT) is used for laboratory diagnosis of chronic alcohol abuse. Several earlier studies reported sensitivities of 90% or above for CDT, with a specificity of 90-100%, although other investigators found lower sensitivities. In general, CDT has been reported to be highly specific (92%) and relatively sensitive (80%) for the detection and monitoring of **alcoholism**. There are no correlation between CDT concentration and gamma-GT activity. Any alteration in serum total **transferrin** concentration markedly decreases the CDT assay specificity. This should be considered when interpreting the assay results in patients with elevated serum **transferrin**. There are differences between the CDT isoforms (**asialo**-Tf and **monosialo**-Tf) in males and females relative to **alcohol consumption**. **Alcohol consumption** increases the levels of **asialo**-Tf and **monosialo**-Tf in women more strongly than in men. Sensitivity of CDT assay is also related to age of patients. There is a significantly higher sensitivity of CDT in patients above 40 years of age as compared to younger patients. The measurement of **carbohydrate-deficient transferrin** may be used as a marker of excessive alcohol abuse in patients with liver diseases

(also in cirrhosis). The specificity of CDT in patients with non-alcoholic liver disease was consistently higher than that of gamma-GT (80% vs 60%). Disulfiram therapy during detoxification does not influence the serum level of CDT.

L52 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2000 ACS

1998:800076 Document No. 130:34380 An improved method for diagnosing alcohol

abuse. Sillanaukee, Pekka (Pharmacia & Upjohn Diagnostics Ab, Swed.). PCT Int. Appl. WO 9854576 A1 19981203, 34 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1998-SE1016

19980528.

PRIORITY: SE 1997-2020 19970529.

AB A method for diagnosing alc. abuse of an individual is characterized in that the levels of **carbohydrate-deficient transferrins** (marker 1) and at least one liver status marker (marker 2) are measured in a body fluid sample whereafter the levels for the markers are weighted to a common value according to a formula giving

a

better sensitivity and/or specificity than obtained for either or both of the markers, said value then being correlated to alc. abuse.

L52 ANSWER 7 OF 15 MEDLINE

DUPLICATE 3

1999085956 Document Number: 99085956. Optimized determination of

**carbohydrate-deficient transferrin** isoforms in serum by capillary zone electrophoresis. Tagliaro F; Crivellente F; Manetto G; Puppi I; Deyl Z; Marigo M. (Institute of Forensic Medicine, University of Verona, Italy.. ftmedl@borgoroma.univ.it) .

ELECTROPHORESIS,

(1998 Nov) 19 (16-17) 3033-9. Journal code: ELE. ISSN: 0173-0835. Pub. country: GERMANY: Germany, Federal Republic of. Language: English.

AB **Carbohydrate deficient transferrin** (CDT) is one of the most reliable markers of chronic alcohol abuse. It consists of a group of minor isoforms of human **transferrin** (the main iron transport serum protein) deficient in sialic acid groups (**asialo**, **monosialo** and **disialo**) with a pI > 5.7, while the main **isotransferrin** (**tetrasialo**) has a pI of 5.4. The aim of the present work was to develop a capillary electrophoretic method to determine CDT in serum, suitable for routine use as a confirmatory technique of the current screening methods based on immunoassays. Serum samples (0.5 mL) were saturated with iron by incubation with 10 mM FeCl3 (9 microL) and 500 mM NaHCO3 (12 microL) for 30 min, then diluted 1/10 in water and injected by positive pressure (0.5 psi for 10 s). Separation

was

performed with a capillary zone electrophoretic method using bare fused-silica capillaries (20 microm ID, 37 cm in length) and a buffer composed of 100 mM sodium tetraborate adjusted with boric acid to pH 8.3. Applied voltage was 10 kV and temperature 25 degrees C. Detection was by UV absorption at 200 nm wavelength. Under the described conditions, **asialo-**, **monosialo-**, **disialo-**, **trisialo-** and **tetrasialo-transferrin** were separated in human serum. The limit of detection (signal-to-noise ratio

of

2) was about 0.3% for **disialo-transferrin**, and 0.4% of

Prepared by M. Hale 308-4258

Page 14

**trisialo-transferrin**, expressed as percentages of the **terasialo-transferrin** peak area. Relative standard deviations (RSD) of absolute migration times were < 1%, while RSD of relative migration times (on the basis of **tetrasialo-transferrin**) were < 0.1%. Intra-day and day-to-day peak quantitation precision studies showed RDS ranging from 4 to 9% and from 13 to 24% for **disialo-** and **trisialo-transferrin**, respectively. The results from 30 control subjects, including social drinkers, and 13 alcoholics showed **disialo-** and **trisialo-transferrin** significantly increased in patients by a factor of about 4.5 ( $P < 0.0001$ ).

L52 ANSWER 8 OF 15 MEDLINE

DUPLICATE 4

1998209925 Document Number: 98209925. Validation by isoelectric focusing of the anion-exchange **isotransferrin** fractionation step involved in determination of **carbohydrate-deficient transferrin** by the CDTest assay. Arndt T; Hackler R; Kleine T O; Gressner A M. (Abteilung für Klinische Chemie und Zentrallaboratorium, Philipps-Universität, Marburg, Germany.. bioscientia@t-online.de) . CLINICAL CHEMISTRY, (1998 Jan) 44 (1) 27-34. Journal code: DBZ. ISSN: 0009-9147. Pub. country: United States. Language: English.

AB Serum concentration of **carbohydrate-deficient transferrin** (CDT) is used for laboratory diagnosis of chronic alcohol abuse. Using isoelectric focusing for validation of the initial **isotransferrin** fractionation step involved in the determination of CDT by the CDTest assay, we found a complete in vitro iron saturation of **transferrin** and sufficient stability of the **transferrin** iron load during column passage; effective separation of non-CDT-**isotransferrins** and CDT-**isotransferrins** at the microcolumns; partial coelution of **trisialo-Fe2-transferrin**, which did not significantly affect CDT measurement; partial retention of CDT-**isotransferrins**, especially **disialo-Fe2-transferrin**, which may cause falsely negative results for CDT at the upper reference limits; good precision of the **isotransferrin** fractionation step; and no significant effects of low concentrations of serum protein and **transferrin**. We strongly urge standardization of CDT analysis and suggest isoelectric focusing for validation of CDT analysis methods and verification of odd results.

L52 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2000 ACS

DUPLICATE 5

1997:750017 Document No. 128:1015 Analysis of **carbohydrate deficient transferrin** by capillary zone electrophoresis. Prasad, Rajani; Stout, Robert L.; Coffin, David; Smith, James (Clinical Reference Laboratory, Lenexa, KS, 66215, USA). Electrophoresis, 18(10), 1814-1818 (English) 1997. CODEN: ELCTDN. ISSN: 0173-0835. Publisher: Wiley-VCH Verlag GmbH.

AB A capillary zone electrophoresis was reported to sep. the various sialylated isoforms of **transferrin**. The sepn. is carried out under nondenaturing conditions and at basic pH. Under these conditions, **transferrin** exhibits 2 major and 3 minor peaks. Blood plasma samples from a population consuming varying amts. of alc. at different intervals were studied. A cut-off value of 3% **carbohydrate deficient transferrin** (CDT: **disialo**, **monosialo**, and **asialo transferrin**), results in a clin. sensitivity of 88% in a population consuming at least 70 g/day

Prepared by M. Hale 308-4258

Page 15



alc. for a min. of 2 wk. The sensitivity dropped in a population consuming less than 70 g/day. This confirms previous reports of CDT as a specific marker for significant and chronic use of alc. Capillary electrophoresis offers an alternative method with respect to anal. time and throughput in the clin. lab.

L52 ANSWER 10 OF 15 MEDLINE DUPLICATE 6

1998099372 Document Number: 98099372. **Transferrin isoform**  
distribution: gender and **alcohol consumption**.  
Martensson O; Harlin A; Brandt R; Seppa K; Sillanauke P. (Pharmacia & Upjohn AB, Diagnostics, Alcohol Related Diseases, Uppsala, Sweden. )  
ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH, (1997 Dec) 21 (9) 1710-5.  
Journal code: 35X. ISSN: 0145-6008. Pub. country: United States.

Language:

English.

AB **Transferrin** (Tf) has different isoforms based on the degree of sialylation of its two N-linked oligosaccharide chains. The least sialylated isoforms of Tf; with 0 (**asialo** Tf), 1 (**monosialo** Tf), and 2 (**disialo** Tf) sialic acids are referred to as **carbohydrate-deficient transferrin** (CDT). CDT has been reported to be a specific and sensitive marker for the detection and monitoring of alcohol abuse. However, the possible differences between the three CDT isoforms in males and females relative to **alcohol consumption** has not been known. The present study included 82 males (M) and 43 females (F) with well documented drinking habits. The Tf isoforms were separated by FPLC and measured by RIA in the collected fractions, as well as by a commercially available method (CDTect RIA). The results were expressed as relative values and absolute values. Female low consumers compared to

male

low consumers had higher levels of **asialo** Tf ( $p < 0.01$ ) and **monosialo** Tf ( $p < 0.01$ ), but not of **disialo** Tf or sum of **asialo**, **monosialo**, and **disialo** Tf. Male high consumers and chronic consumers compared to male low consumers had 53%

and

219% higher levels of **asialo** Tf, 4% and 28% higher **monosialo** Tf, 57% and 148% higher **disialo** Tf, and 48% and 134% higher sum of CDT isoforms, respectively. The corresponding increases in females were for **asialo** Tf 68% and 249%, for **monosialo** Tf 36% and 58%, for **disialo** Tf 54% and 225%, and for sum of CDT isoforms 52% and 192%, respectively. For both genders, total Tf, **trisialo** Tf, and the levels of more sialylated **transferrin** isoforms were constant when comparing the consumption groups. Results expressed as relative values and absolute values were in good agreement. In conclusion, the present study indicates that **alcohol consumption** strongly increases the levels of **asialo** Tf and **disialo** Tf and slightly increases the level of **monosialo** Tf. However, women had higher **asialo** Tf and **monosialo** Tf levels than men. **Alcohol consumption** does not increase **trisialo** or more sialylated Tf subfractions. Expressing the CDT results as absolute or relative

values

made no obvious difference in diagnostic efficiency.

L52 ANSWER 11 OF 15 MEDLINE DUPLICATE 7

97221546 Document Number: 97221546. Quantification of **carbohydrate**  
Prepared by M. Hale 308-4258 Page 16

-deficient transferrin by ion-exchange chromatography  
with an enzymatically prepared calibrator. Renner F; Kanitz R D.

(Institut

fur Klinische Chemie, Medizinische Universitat zu Lubeck, Germany. )  
CLINICAL CHEMISTRY, (1997 Mar) 43 (3) 485-90. Journal code: DBZ. ISSN:  
0009-9147. Pub. country: United States. Language: English.

AB The current HPLC method for the determination of **carbohydrate-**  
**deficient transferrin** (CDT) yields ratios of CDT  
isoforms in relation to total **transferrin**, whereas the use of  
absolute concentrations obtainable in routine analysis by RIA and the  
reference ranges based here-upon is more convenient. We describe a  
modified HPLC method that likewise gives absolute CDT concentrations by  
using a calibrator prepared by treatment of **transferrin** with  
neuraminidase. Separation of isoforms could be improved and analysis time  
reduced to approximately 2 h. Iron saturation proved stable during  
chromatography. In contrast to a commercial RIA, the cheaper and more  
time-saving HPLC method excludes erroneous results caused by aged samples  
or genetic **transferrin** variants and enables the determination of  
**asialo-** and **disialotransferrin**. Both methods showed  
comparable precision and correlated with each other ( $y = 1.76 + 0.27x$ ;  
 $Sy[\text{symbol: see text}]x = 5.38$ ); for the HPLC method precision was 1.3-9.8%  
(within assay) and 6.2-10.6% (between assay). The clinical evaluation

with

a cutoff concentration of 80 mg/L resulted in a diagnostic specificity of  
100% and a sensitivity of 82.5%.

L52 ANSWER 12 OF 15 MEDLINE

DUPLICATE 8

97033627 Document Number: 97033627. Should tri-sialo-**transferrins**  
be included when calculating **carbohydrate-deficient**  
**transferrin** for diagnosing elevated alcohol intake?. Heggli D E;  
Aurebekk A; Granum B; Westby C; Lovli T; Sundrehagen E. (Axis

Biochemicals

AS, Oslo, Norway. ) ALCOHOL AND ALCOHOLISM, (1996 Jul) 31 (4) 381-4.  
Journal code: AAL. ISSN: 0735-0414. Pub. country: ENGLAND: United

Kingdom.

Language: English.

AB CDT (**carbohydrate-deficient transferrin**) has  
been identified as a specific marker for chronically elevated  
**alcohol consumption**. We investigated the sensitivity and  
accuracy of using relative concentrations of different  
**isotransferrins** in serum for diagnosis of chronically elevated  
**alcohol consumption**. The different **transferrin**  
variants (isoforms) were quantified by HPLC. Including the  
**trisialo-transferrin** fraction into the definition of  
%CDT resulted in an increased accuracy in the detection of chronically  
elevated alcohol intake in a study among 17 heavy drinkers, 25 healthy  
individuals with moderate **alcohol consumption** and nine  
total abstainers. The results also suggest that desialylation of  
**transferrin** is a gradually continuing process, rather than one  
leading to a single end-result separating **asialo-**, mono- and  
**disialo-transferrins** from **trisialo-**,  
**tetrasialo-**, **pentasialo-** and higher sialo-  
**transferrins**.

L52 ANSWER 13 OF 15 MEDLINE

DUPLICATE 9

95150262 Document Number: 95150262. Comparison of different methods for  
Prepared by M. Hale 308-4258 Page 17

detecting **carbohydrate-deficient transferrin**

. Sillanauke P; Lof K; Harlin A; Martensson O; Brandt R; Seppa K.  
(Biomedical Research Center, Alko Ltd., Helsinki, Finland. ) **ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH**, (1994 Oct) 18 (5) 1150-5. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB Different methods for detecting **carbohydrate-deficient transferrin** (CDT) were compared. In addition, their efficiency for detecting alcohol abuse among men not having clinical evidence of liver disease was studied in controls (n = 26), weekend (n = 16) and daily (n = 12) heavy drinkers, and alcoholics (n = 28). Comparisons were made between

anion-exchange separation of iron-saturated **transferrin** (Tf) by microcolumns (CDTect) and by the Fast Protein Liquid Chromatography (FPLC)

and FPLC-MG), followed by double-antibody radioimmunoassay of collected fractions. Tf fractions with pI > or = 5.7 were also measured by two different isoelectric focusing (IEF) methods, followed by immunofixation (SA-IEF-CDT and IEF-CDT-TOT), the latter method being used also for detection of **asialotransferrin** (IEF-CDT-AS). The cut-off was 20 units/liter for CDTect, 4.4% of total Tf for SA-IEF-CDT, and the mean +2 sd of the control group for FPLC-MG (as mg/liter of Tf), FPLC-%, IEF-CDT-TOT, and IEF-CDT-AS (all as percentage of Tf). The overall accuracies (combining sensitivity and specificity) for detecting heavy drinkers of CDTect, FPLC (mg/liter), FPLC (%), SA-IEF-CDT, IEF-CDT-TOT, and IEF-CDT-AS were 63%, 59%, 61%, 74%, 57%, and 63%, respectively; for detecting alcoholics, 87%, 83%, 81%, 89%, 37%, and 76%, respectively. In conclusion, the methods were in rather good agreement with each other. Diagnostic characteristics among heavy drinkers and correlations between methods differed slightly, probably depending on the ability of different methods to separate and detect **asialo-**, **monosialo-**, and **disialotransferrin**. (ABSTRACT TRUNCATED AT 250 WORDS)

L52 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2000 ACS

1993:227670 Document No. 118:227670 Desialylated **transferrin**. A new approach in diagnosis of **alcoholism**. Wedig, M. P. (Klin. Eichholz, Bad Waldliesborn, Germany). Mol. Cell Biol. Liver

Fibrogenesis,

Proc. Int. Falk Symp., 548-50. Editor(s): Gressner, A. M.; Ramadori, G. Kluwer: Dordrecht, Neth. (English) 1992. CODEN: 58ZZAF.

AB Recently, desialylated **transferrin** (dTf, also known as **carbohydrate-deficient transferrin**) and the mitochondrial isoenzyme of aspartate aminotransferase have been proposed as being more sensitive and specific biochem. markers of alc. abuse than are conventional lab. tests. Abnormal **transferrin** variants with less sialic acid content were found in the serum of alc. subjects.

L52 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2000 ACS

1994:47907 Document No. 120:47907 Sialic acid-deficient **transferrin**: a very attractive biological marker related to chronic **alcoholism**. Renversez, J. C.; Alzieu, C.; Vernet, M. (Lab. Biochim. A, CHRU de Grenoble, Grenoble, 38043, Fr.). Ann. Biol. Clin., 50(1), 1-7 (French) 1992. CODEN: ABCLAI. ISSN: 0003-3898.

AB Sialic acids-deficient **transferrins**: a very attractive biol. marker related to chronic **alcoholism**. Chronic **alcoholism** may induce modifications of plasma **transferrin**

: alc. modifies the content of its branched oligosaccharides. The abnormal **transferrin** contains reduced amts. of sialic acids, constituting its terminal trisaccharides biantennary chains. Plasma levels of partly deficient or **asialotransferrin** (**carbohydrate-deficient transferrin** or CDT) increase in chronically drinkers. A pos. correlation is obtained between the plasmatic concn. of CDT and the amt. of ingested alc. Positivity and sensitivity of CDT are superior to those of other usual biol. parameters. The CDT quantitation may be used for the detection and the follow-up of **alc. drinkers** to evaluate the degree of intoxication, and during the period of withdrawal.

=> s 137 not 144

L53	252	FILE	MEDLINE
L54	131	FILE	CAPLUS
L55	238	FILE	BIOSIS
L56	245	FILE	EMBASE
L57	3	FILE	WPIDS
L58	1	FILE	JICST-EPLUS

TOTAL FOR ALL FILES

L59 870 L37 NOT L44

=> s 159 not 115

L60	252	FILE	MEDLINE
L61	130	FILE	CAPLUS
L62	238	FILE	BIOSIS
L63	245	FILE	EMBASE
L64	1	FILE	WPIDS
L65	1	FILE	JICST-EPLUS

TOTAL FOR ALL FILES

L66 867 L59 NOT L15

=> s 166 and (bind? ligand or lectin?)

L67	4	FILE	MEDLINE
L68	2	FILE	CAPLUS
L69	2	FILE	BIOSIS
L70	1	FILE	EMBASE
L71	0	FILE	WPIDS
L72	0	FILE	JICST-EPLUS

TOTAL FOR ALL FILES

L73 9 L66 AND (BIND? LIGAND OR LECTIN?)

=> dup rem 173

PROCESSING COMPLETED FOR L73

L74 6 DUP REM L73 (3 DUPLICATES REMOVED)

=> d cbib abs 1-6

L74 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS

2000:384553 Document No. 133:28245 Diagnosis of human glycosylation disorders. Marth, Jamey D.; Freeze, Hudson H. (The Regents of the University of California, USA; The Burnham Institute). PCT Int. Appl. WO 2000033076 A1 20000608, 95 pp. DESIGNATED STATES: W: AE, AL, AM, AT,

AU,

AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US28591 19991201. PRIORITY: US 1998-PV110671 19981202; US 1998-PV113680 19981221; US 1998-PV114174 19981230.

AB This invention provides methods and kits for use in diagnosing genetically

transmitted diseases that are assocd. with deficiencies in glycosylation of glycoconjugates such as glycoproteins, glycolipids, and proteoglycans. The methods and kits are also useful for monitoring the course of treatment of diseases that are assocd. with glycosylation disorders.

Blood from patient with **carbohydrate-deficient**

glycoprotein syndrome (CDGS) type II did not bind to E-PHA

(erythroagglutinin of Phaseolus vulgaris ) or to L-PHA (leucoagglutinin

of

Phaseolus vulgaris) **lectins** but showed increased binding to ConA

**lectin**. Mouse models were constructed having defects in certain

enzyme genes and the models were studied.

L74 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

2000:374337 Document No.: PREV200000374337. Glycobiological and clinical similarity between patients with alcoholic liver disease and **carbohydrate-deficient** glycoprotein syndrome (CDGS).

Yamauchi, M. (1); Inoue, T. (1); Searashi, Y. (1); Nishikawa, F. (1);

Ohata, M. (1); Toda, G. (1); Ohkawa, K.. (1) Department of Internal

Medicine, Jikei University School of Medicine, Tokyo Japan. Alcoholism

Clinical and Experimental Research, (May, 2000) Vol. 24, No. 5

Supplement,

pp. 205A. print. Meeting Info.: Tenth Congress of the International

Society for Biomedical Research on Alcoholism Yokohama, Japan July 02-08,

2000 Research Society on Alcoholism. ISSN: 0145-6008. Language: English.

Summary Language: English.

L74 ANSWER 3 OF 6 MEDLINE

DUPLICATE 1

1999412174 Document Number: 99412174. Determination of **carbohydrate**

**-deficient transferrin** separated by **lectin**

affinity chromatography for detecting chronic alcohol abuse. Yoshikawa K;

Umetsu K; Shinzawa H; Yuasa I; Maruyama K; Ohkura T; Yamashita K; Suzuki

T. (Department of Forensic Medicine, Yamagata University School of

Medicine, Japan. ) FEBS LETTERS, (1999 Sep 17) 458 (2) 112-6. Journal

code: EUH. ISSN: 0014-5793. Pub. country: Netherlands. Language: English.

AB **Carbohydrate-deficient transferrin** (CDT) has

been established as a valuable biological marker for detecting chronic

alcohol abuse. To improve the diagnostic efficiency, we studied new CDT

determination procedures involving the use of **lectin** affinity

Prepared by M. Hale 308-4258

Page 20

chromatography with Allomyrina dichotoma agglutinin (allo A) and Trichosanthes japonica agglutinin I (TJA-I) to isolate the CDT isoforms CDT-allo A and CDT-TJA, respectively. These procedures, based on detection of the CDT-allo A and CDT-TJA isoforms in sera, showed high sensitivity (100% and 98%, respectively) and high specificity (93% and 85%, respectively). These results demonstrate that the new procedures involving the use of **lectin** affinity chromatography are more useful for isolating markers in the CDT test than the conventional charge-based separation method.

L74 ANSWER 4 OF 6 MEDLINE

1998207678 Document Number: 98207678. Identification of **carbohydrate deficient transferrin** forms by MALDI-TOF mass spectrometry and **lectin** ELISA Biochim Biophys Acta 1998 Aug 24;1381(3):356. Peter J; Unverzagt C; Engel W D; Renauer D; Seidel C; Hosel W. (Institut fur Organische Chemie und Biochemie, Technische Universitat Munchen, Garching, Germany. ) BIOCHIMICA ET BIOPHYSICA ACTA, (1998 Mar 12) 1380 (1) 93-101. Journal code: AOW. ISSN: 0006-3002. Pub. country: Netherlands. Language: English.

AB **Transferrin** was isolated from sera of patients with severe alcohol abuse and from control sera by affinity chromatography using an immobilized polyclonal antibody from sheep, followed by gel filtration. The purified **transferrin** was then separated by MonoQ chromatography. Compared to the controls, sera from heavy alcohol consumers showed two additional **transferrin** peaks, eluting earlier than the three main **transferrin** forms present in all sera. Further analysis of the isolated **transferrin** forms by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) and enzyme linked immunosorbent assay with different digoxigenylated **lectins** (**lectin** ELISA) revealed that the main **carbohydrate deficient transferrin** (CDT) forms are lacking either one or both of the N-Glycan chains.

L74 ANSWER 5 OF 6 MEDLINE

97139638 Document Number: 97139638. Microheterogeneity with concanavalin A affinity of serum **transferrin** in patients with alcoholic liver disease. Inoue T; Yamauchi M; Toda G; Ohkawa K. (Tikei University School of Medicine, Tokyo, Japan. ) ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH, (1996 Dec) 20 (9 Suppl) 363A-365A. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB Microheterogeneity of **transferrin** (Tf) with concanavalin A (ConA) affinity was investigated by sensitive **lectin**-affinity electrophoresis and antibody-affinity blotting technique of sera obtained from patients with alcoholic liver disease (ALD) and normal subjects. Serum Tf was separated by ConA into three bands-a strongly ConA-reactive major band (C1), a weakly reactive minor band (C2), and a non-reactive trace band (C3). The C3 fraction was significantly increased in patients with ALD before alcohol abstinence, compared with normal subjects and patients with ALD after 4 weeks of abstinence. Furthermore, a significant correlation was found between the C3 fraction and serum **carbohydrate-deficient transferrin** or gamma-glutamyl-transpeptidase. These results indicate that the microheterogeneity of serum Tf in patients with ALD may be a more complex

abnormality of elongation and processing on the glycans than merely a loss of terminal sialic acids. Determination of the C3 fraction is a useful marker for ALD.

L74 ANSWER 6 OF 6 MEDLINE

DUPLICATE 2

96176959 Document Number: 96176959. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Gravel P; Walzer C; Aubry C; Balant

L

P; Yersin B; Hochstrasser D F; Guimon J. (Clinical Research Unit, Psychiatric University Institutions of Geneva, Switzerland. ) BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 Mar 7) 220 (1) 78-85. Journal code: 9Y8. ISSN: 0006-291X. Pub. country: United States.

Language:

English.

AB Plasma protein are synthesized and secreted by the liver. Several reports have shown that excessive consumption of ethanol interferes with the hepatic protein synthesis and/or secretion. This study was undertaken to identify the plasma/serum proteins altered in two groups of patients with different alcohol-related diseases: actively drinking alcoholic patients group without liver disease and alcohol cirrhotic patients group. Two-dimensional gel electrophoresis was used to separate proteins with high resolution. Proteins were detected by silver staining and glycoproteins were specifically visualized and analyzed after lectin blotting followed by chemiluminescence detection. Different protein alterations were identified in each group of patients. In the alcoholic group, two new glycosylation modifications of serum proteins were identified. An abnormal microheterogeneity of haptoglobin and alpha1-antitrypsin was detected in the serum of all alcoholic patients.

We

also characterized by two-dimensional gel electrophoresis the carbohydrate deficient transferrin. The modifications of haptoglobin, alpha1-antitrypsin and transferrin present a similar change of charge and molecular weight in the two-dimensional gel electrophoresis pattern. These qualitative

estimations

support the hypothesis of a general mechanism of liver glycosylation alteration of serum proteins induced by excessive alcohol consumption. The immunoglobulin alterations were easily visualized and identified for the cirrhotic and the alcoholic patients. And finally, the decrease of haptoglobin and albumin spots for cirrhotic patients was confirmed.

=> s 166 not 173

L75 248 FILE MEDLINE

L76 128 FILE CAPLUS

L77 236 FILE BIOSIS

L78 244 FILE EMBASE

L79 1 FILE WPIDS

L80 1 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L81 858 L66 NOT L73

Prepared by M. Hale 308-4258

Page 22

=> s (sambuc? or maack? or escherchia or helicobacter or ricin? or crotalar?  
or anti sialic acid) (5a) lectin and l81

L82	0	FILE MEDLINE
L83	0	FILE CAPLUS
L84	0	FILE BIOSIS
L85	0	FILE EMBASE
L86	0	FILE WPIDS
L87	0	FILE JICST-EPLUS

TOTAL FOR ALL FILES

L88	0	(SAMBUC? OR MAACK? OR ESCHERCHIA OR HELICOBACTER OR RICIN? OR CROTALAR? OR ANTI SIALIC ACID) (5A) LECTIN AND L81
-----	---	---

=> s l81 and blood

L89	224	FILE MEDLINE
L90	79	FILE CAPLUS
L91	87	FILE BIOSIS
L92	132	FILE EMBASE
L93	1	FILE WPIDS
L94	1	FILE JICST-EPLUS

TOTAL FOR ALL FILES

L95	524	L81 AND BLOOD
-----	-----	---------------

=> s l81 and body fluid

L96	0	FILE MEDLINE
L97	2	FILE CAPLUS
L98	1	FILE BIOSIS
L99	0	FILE EMBASE
L100	1	FILE WPIDS
L101	0	FILE JICST-EPLUS

TOTAL FOR ALL FILES

L102	4	L81 AND BODY FLUID
------	---	--------------------

=> s (l95 or l102) and (determ? or detm or method)

L103	109	FILE MEDLINE
L104	49	FILE CAPLUS
L105	57	FILE BIOSIS
L106	68	FILE EMBASE
L107	1	FILE WPIDS
L108	0	FILE JICST-EPLUS

TOTAL FOR ALL FILES

L109	284	(L95 OR L102) AND (DETERM? OR DETM OR METHOD)
------	-----	---

=> s l109 and (separat? or precipit? or centrifug? or filt? or chromatograph?)

L110	31	FILE MEDLINE
L111	18	FILE CAPLUS
L112	14	FILE BIOSIS



L113 19 FILE EMBASE  
L114 0 FILE WPIDS  
L115 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L116 82 L109 AND (SEPARAT? OR PRECIPIT? OR CENTRIFUG? OR FILT? OR  
CHROMA

TOGRAPH?)

=> s l116 and (turbidomet? or nephelomet?)

L117 1 FILE MEDLINE  
L118 1 FILE CAPLUS  
L119 0 FILE BIOSIS  
L120 1 FILE EMBASE  
L121 0 FILE WPIDS  
L122 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L123 3 L116 AND (TURBIDOMET? OR NEPHELOMET?)

=> s l116 and kit

L124 7 FILE MEDLINE  
L125 2 FILE CAPLUS  
L126 5 FILE BIOSIS  
L127 5 FILE EMBASE  
L128 0 FILE WPIDS  
L129 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L130 19 L116 AND KIT

=> s l123 or l130

L131 8 FILE MEDLINE  
L132 3 FILE CAPLUS  
L133 5 FILE BIOSIS  
L134 6 FILE EMBASE  
L135 0 FILE WPIDS  
L136 0 FILE JICST-EPLUS

TOTAL FOR ALL FILES

L137 22 L123 OR L130

=> dup rem l137

PROCESSING COMPLETED FOR L137

L138 10 DUP REM L137 (12 DUPLICATES REMOVED)

=> d 1-10 cbib abs;s l109 and assay

L138 ANSWER 1 OF 10 MEDLINE DUPLICATE 1  
2000260921 Document Number: 20260921. Biological markers of  
alcoholism with respect to genotypes of low-Km aldehyde  
Prepared by M. Hale 308-4258

dehydrogenase (ALDH2) in Japanese subjects. Nomura F; Itoga S; Tamura M; Harada S; Iizuka Y; Nakai T. (Institute of Clinical Medicine, Tsukuba University, Tokyo, Japan. ) ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH, (2000 Apr) 24 (4 Suppl) 30S-33S. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB BACKGROUND: Although the mutant low-Km acetaldehyde dehydrogenase (ALDH2) allele (ALDH2(2)) with reduced capacity to metabolize acetaldehyde offers biological protection against **alcoholism** and subsequent alcohol-induced organ damage in many individuals, a significant proportion

of individuals with heterozygote of the normal and mutant ALDH2 gene (ALDH2(1)/2(2)) consume excessive amounts of alcohol. Indeed, it has been postulated that habitual drinkers with ALDH2(1)/2(2) may be at a higher risk for alcoholic liver disease than those with ALDH2(1)/2(1). In this study, we **determined** how representative biological markers of **alcoholism** (gamma-glutamyltransferase [GGT], **carbohydrate-deficient transferrin** [CDT], and the mean corpuscular volume of erythrocytes [MCV]) differ with respect to the ALDH2 genotypes in Japanese habitual drinkers. **METHODS:** We obtained genomic DNA samples from 227 Japanese men with various drinking habits. ALDH2 genotypes were **determined** by allele-specific polymerase chain reaction. GGT, CDT, and MCV were **determined** and compared between ALDH2(1)/2(1) and ALDH2(1)/2(2) habitual drinkers who consumed more than 66 g of alcohol per day for more than 5 years. We measured CDT by anion-exchange **chromatography** followed by turbidity immunoassay by using a commercially available assay kit (Axis %CDT TIA). **RESULTS:** CDT levels were comparable between the two groups. GGT

activities

were significantly greater in ALDH2(1)/2(1) than in ALDH2(1)/2(2)

habitual

drinkers (81 +/- 85 vs. 53 +/- 40 IU/liters,  $p < 0.02$ ). MCV values, on

the

other hand, were significantly larger in ALDH2(1)/2(2) than in ALDH2(1)/2(1) subjects (98.2 +/- 5.8 vs. 95.8 +/- 4.2 fl,  $p = 0.02$ ). When we used elevation of either CDT or GGT to detect habitual drinking in ALDH2(1)/2(1) and 2(1)/2(2) subjects, the sensitivities were 57% and 46%, respectively. CDT levels were similar between habitual drinkers with normal aspartate aminotransferase levels and those with elevated levels. **CONCLUSION:** GGT and MCV, but not CDT, differ with respect to the ALDH2 genotypes in Japanese male habitual drinkers. ALDH2 genotypes should be considered when interpreting data on biological markers of **alcoholism**.

L138 ANSWER 2 OF 10 MEDLINE

DUPLICATE 2

96189048 Document Number: 96189048. **Nephelometric**

**determination of carbohydrate deficient**

**transferrin.** Schellenberg F; Martin M; Cac'es E; Benard J Y; Weill

J. (Laboratory of Biochemistry, CHU Trousseau, Tours, France. ) CLINICAL CHEMISTRY, (1996 Apr) 42 (4) 551-7. Journal code: DBZ. ISSN: 0009-9147.

Pub. country: United States. Language: English.

AB We describe a technique for measuring **carbohydrate-deficient transferrin** (CDT) in serum. Serum **transferrin** fractions are **separated** by anion-exchange **chromatography** on microcolumns. Sialic acid-deficient **transferrin** fractions are collected in the eluate, and **transferrin** is then quantified by a rate-**nephelometric**

Prepared by M. Hale 308-4258

Page 25

technique. Imprecision (CV) was 4-5% within-run and 7-9% between runs (n

15). Comparison with an isoelectric focusing-immunofixation method for transferrin index (x) yielded  $y = 761x + 7$ ,  $Sy/x = 39$  mg/L.

Assay of sera from 90 abstainers or moderate consumers of alcohol showed that 81 (90%) had CDT concentrations between 30 and 70 mg/L. Among 74 alcoholics admitted to an alcohol treatment center, 54 (73%) had CDT > 70 mg/L, i.e., the diagnostic sensitivity was 73% at a specificity of 90% (area under receiver-operator characteristic curve = 0.891).

L138 ANSWER 3 OF 10 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.

96291441 EMBASE Document No.: 1996291441. [AXIS% CDT RIA - A new marker of alcohol abuse]. AXIS% CDT RIA - NOVY TEST PRO PRUKAZ ABUZU ALKOHOLU.

Fingerova H.; Urbanek K.; Buresova J.. Porodnicka a Gynecologicka

Klinika,

Lekarska Fakulta, Univerzita Palackeho, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic. Klinicka Biochemie a Metabolismus 4/3 (170-172) 1996. ISSN: 1210-7921. CODEN: KBMEFQ. Pub. Country: Czech Republic. Language: Czech. Summary Language: English; Czech.

AB Our first experience with a new test for simple and rapid detection of chronic high alcohol consumption in neurological patients is presented. The AXIS% CDT RIA kit uses an integrated separation and quantitation technique to measure the relative amount of carbohydrate-deficient transferrin (% CDT) in serum. So far, one hundred tests (two kits for 50 determinations) were performed on 70 serum samples from patients treated for neurological disorders and suspected of alcohol abuse during treatment, control individuals and out-patients with professional risk of liver damage. The preliminary evaluation and clinical interpretation give evidence of a significant reliability of the chosen analytical approach.

L138 ANSWER 4 OF 10 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.

96289982 EMBASE Document No.: 1996289982. Reliability of carbohydrate-deficient transferrin to detect chronic alcohol

misuse in carcinoma patients. Spies C.D.; Von Winterfeld A.; Muller C.; Rommelspacher H.; Neumann T.; Marks C.; Berger G.; Conrad C.; Blum S.; Hannemann L.; Striebel H.W.; Schaffartzik W.. Klin Anaesthesiol operat Intensivmed, Universitätsklinik Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, D-12000 Berlin, Germany. European Addiction Research 2/3 (156-162) 1996.

ISSN: 1022-6877. CODEN: EADREE. Pub. Country: Switzerland. Language: English. Summary Language: English.

AB The patients' history and conventional laboratory markers are often not sensitive or specific enough to detect chronic alcohol misuse, preoperatively. We investigated whether carbohydrate-deficient transferrin (CDT), determined with a new commercially available kit, is a more sensitive and specific marker to detect chronic alcohol misuse in these patients and we compared it to a CDT research kit and to other conventional laboratory markers. 153 patients with oral, pharyngeal, laryngeal or esophageal carcinomas were evaluated regarding their drinking habits. Chronic alcohol misuse was diagnosed if the daily ethanol intake was  $\geq 60$  g and the patient met the DSM-III-R criteria for chronic alcohol abuse or dependence. CDTs and the conventional laboratory markers were sampled on admission of the patients, preoperatively,

postoperatively

following admission to the ICU and on day 2, 4 and 7 in the ICU. CDT was **determined** by microanion exchange **chromatography** and turbidimetry (research kit) and microanion exchange **chromatography** and radioimmunoassay (commercially available CDT kit), respectively. The investigators were blinded to the CDT results. For all patients admitted to the hospital the sensitivity of the CDT research kit was 74% and for the commercially available CDT kit 77%. Specificity was 100% for the CDT research kit and 97% for the commercially available CDT kit. Both CDT kits were more accurate in detecting chronic alcohol misuse than any other conventional laboratory marker over a range of cutoffs evaluated

by receiver operating characteristic curves. Since the CDT values on admission were significantly correlated with the length of ICU stay (CDT research kit:  $r(s) = 0.56$ ;  $p = 0.000$ ; commercially available CDT:  $r = 0.39$ ;  $p = 0.009$ ) and since investigated chronic alcoholics developed more complications in the ICU and had a prolonged ICU stay, it seems reasonable to **determine** serum CDT, the most sensitive and specific marker of chronic alcohol misuse. Patients with pathologically elevated CDT values should be further evaluated and managed accordingly.

L138 ANSWER 5 OF 10 MEDLINE

DUPLICATE 3

97039828 Document Number: 97039828. Post mortem markers of chronic **alcoholism**. Sadler D W; Girela E; Pounder D J. (Department of Forensic Medicine, University of Dundee, Royal Infirmary, UK. ) FORENSIC SCIENCE INTERNATIONAL, (1996 Sep 30) 82 (2) 153-63. Journal code: F49. ISSN: 0379-0738. Pub. country: Ireland. Language: English.

AB We compared the post mortem diagnostic value of gamma-glutamyltransferase (GGT), **carbohydrate-deficient transferrin** (CDT), alcoholic liver disease (ALD), **blood** alcohol concentration (BAC), the presence of multiple bruises and poor hygiene of the feet as markers of chronic **alcoholism** (heavy continuous drinking) in 32 alcoholics with 32 age-sex matched controls drawn from a forensic autopsy population. Alcoholics and controls were selected on the basis of positive and negative medical history but controls were excluded if BAC exceeded 70 mg%. Femoral venous **blood**, urine and vitreous humour alcohol concentrations were **determined** by headspace gas **chromatography** (GC). BAC was positive in 19 alcoholics (mean 234 mg%, range 2-570 mg%) and six controls (mean 32 mg%, range 2-52 mg%). Serum GGT was measured by a kinetic photometric **method**, and CDT by both isoelectric focusing/laser densitometry and by a commercial radioimmunoassay kit (CDTect). Features of alcoholic liver disease were graded histologically using two weighted scoring systems. Eleven alcoholics tested positive for GGT, CDTq and ALD, nine were positive for two tests, five for one test and three were negative for all three tests. No controls were positive for all three tests but six were positive for two tests and nine for only one test; 17 were negative for all three tests. Using the normal clinical cut-off values GGT, CDTq and CDTect gave poor specificity which was improved at moderate cost to sensitivity by raising cut off values for each test. Comparison of receiver operating characteristic curves, likelihood ratios and post-test odds showed CDT to be the best individual test, followed by ALD and GGT. Quantitation of CDT by IEF/laser densitometry performed slightly better than MAEC/RIA by CDTect. CDT shows considerable promise as a post mortem marker of chronic **alcoholism**.

96042286 Document Number: 96042286. Relevance of **carbohydrate-deficient transferrin** as a predictor of **alcoholism** in intensive care patients following trauma. Spies C D; Emadi A; Neumann T; Hannemann L; Rieger A; Schaffartzik W; Rahmanzadeh R; Berger G; Funk T; Blum S; et al. (Benjamin Franklin Medical Center, Department of Anesthesiology, Berlin, Germany. ) JOURNAL OF TRAUMA, (1995 Oct) 39 (4) 742-8. Journal code: KAF. ISSN: 0022-5282. Pub. country: United States. Language: English.

AB Every second traumatized patient is a chronic alcoholic. Chronic alcoholics are at risk due to an increased morbidity and mortality. Reliable and precise diagnostic **methods** for detecting **alcoholism** are mandatory to prevent posttraumatic complications by adequate prophylaxis. The patient's history, however, is often not reliable, and conventional laboratory markers are not sensitive or specific enough. The aim of this study was to investigate whether **carbohydrate-deficient transferrin** (CDT) is a sensitive and specific marker to detect **alcoholism** in traumatized patients. One hundred and five male traumatized patients or their relatives gave their written informed consent to participate in

this institutionally approved study. All patients were transferred to the intensive care unit after admission to the emergency room, followed by surgical treatment. Diagnostics included an **alcoholism**-related questionnaire, conventional laboratory markers (mean corpuscular volume, gamma-glutamyltransferase, aspartate aminotransferase, and alanine aminotransferase), and CDT sampling (microanion-exchange **chromatography**, turbidimetry, and radioimmunoassay, respectively). Only patients in whom a reliable history could be obtained were included. **Alcoholism** was diagnosed if the patients met the Diagnostic and Statistical Manual of Mental Disorders criteria for chronic alcohol abuse or dependence. The administration of fluids before CDT sampling was carefully documented. Patients did not differ significantly regarding

age, Trauma and Injury Severity Score, and Acute Physiology and Chronic Health Evaluation score. The sensitivity of the CDT research **kit** was 70% and of the commercially available **kit** CDTest was 65%. Early sampling in the emergency room and before administration of large volumes of fluid increased the sensitivity to 83% for the CDT research **kit** and 74% for CDTest, respectively. (ABSTRACT TRUNCATED AT 250 WORDS)

96099603 Document Number: 96099603. [**Carbohydrate-deficient transferrin** and liver diseases. Study of 94 patients]. **Transferrine** deficiente en acide sialique et maladies du foie. Etude de 94 malades. Ouyahya F; Bacq Y; Schellenberg F; Metman E H; Weill J. (Service d'Hepato-Gastroenterologie, Hopital Trousseau, Tours. ) GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, (1995 Aug-Sep) 19 (8-9) 698-702. Journal code: FGX. ISSN: 0399-8320. Pub. country: France. Language: French.

AB OBJECTIVES AND **METHODS**--**Carbohydrate-deficient transferrin** has been proposed as a marker of **alcohol consumption**. The aim of this study was to evaluate the accuracy of the **carbohydrate-deficient transferrin** serum level, measured by ion exchange **chromatography** followed by radioimmunoassay (**Kit** CDTest), for the diagnosis of excessive

Prepared by M. Hale 308-4258

alcohol intake in patients with liver diseases. Ninety-four patients (68 men, 26 women, age 21-71 years), 42 with alcoholic liver diseases and 52 with non-alcoholic liver diseases, were studied. Twenty-six patients consumed > or = 40 g alcohol per day (mean alcohol intake: 84 +/- 52 g

per day) and were considered to be excessive drinkers. RESULTS--The sensitivity of **carbohydrate-deficient transferrin** for the diagnosis of excessive alcohol intake was 35%, and the specificity was 91%. By pairing **carbohydrate-deficient transferrin** with other markers of alcohol consumption, the sensitivity of the association of **carbohydrate-deficient transferrin** and gammaglutamyl transpeptidase was 96%, and the specificity was 59%. CONCLUSION--In patients with liver diseases, **carbohydrate-deficient transferrin** is a specific marker of excessive alcohol intake but a lack of sensitivity may limit its use.

L138 ANSWER 8 OF 10 MEDLINE DUPLICATE 6  
95142434 Document Number: 95142434. [Multicenter study of sialic acid deficient **transferrin** determined by two chromatographic techniques]. Etude multicentrique du dosage de la **transferrine** deficiente en acide sialique par deux techniques chromatographiques. Vernet M; Renversez J C; Revenant M C; Sotta C; Charlier De Bressing C; Benoit M O; Guillemin C; Paris M; Plomteux G. (Laboratoire de biochimie, hopital de la Croix-Rousse, Lyon, France. ) ANNALES DE BIOLOGIE CLINIQUE, (1994) 52 (7-8) 535-46. Journal code: 4ZS. ISSN: 0003-3898. Pub. country: France. Language: French.

AB Serum **carbohydrate-deficient-transferrin** (CDT) was measured by a micro anion-exchange chromatography /enzyme immunoassay. Results obtained on 245 sera analyzed in four laboratories were compared. Moreover, one laboratory used a commercial kit with ready-to-use microcolumns and a radioimmunoassay for measuring eluted CDT. Imprecision was judged to be satisfactory. Within-assay coefficients of variation ranged from 5 to 10%, between-assay coefficients of variation ranged from 9 to 18%. Between-laboratory results were compared for 110 sera from control subjects (daily alcohol intake < 40 g), for 57 sera from chronic ethylic subjects and for 78 sera from patients suffering from non-alcoholic liver diseases. There was a large between-laboratory variation, suggesting that the method is difficult to standardize and that results are not transferable. Results of enzyme and radioimmunoassays were compared on 325 sera. The best correlation was obtained in the groups of ethylic subjects and those with non-alcoholic hepatic diseases. Finally the performance of the CDT-test was evaluated by calculating sensitivity and specificity. With both methods specificity was very high (> 85%) but sensitivity was poor (< 50%).

L138 ANSWER 9 OF 10 MEDLINE  
94271349 Document Number: 94271349. Serum level of **carbohydrate-deficient transferrin** as a marker of alcoholic liver disease. Yamauchi M; Hirakawa J; Maezawa Y; Nishikawa F; Mizuhara Y; Ohata M; Nakajima H; Toda G. (First Department of Internal Medicine, Jikei Prepared by M. Hale 308-4258 Page 29

University School of Medicine, Tokyo, Japan. ) ALCOHOL AND ALCOHOLISM. SUPPLEMENT, (1993) 1B 3-8. Journal code: AAP. ISSN: 1358-6173. Pub. country: ENGLAND: United Kingdom. Language: English.

AB Serum levels of **carbohydrate-deficient transferrin** (CDT) were assayed in 87 patients with alcoholic liver disease, 25 alcoholics without liver disease, 25 cases with viral liver disease and 37 healthy subjects, by two different **methods** (Pharmacia CDT RIA kit and Axis % CDT kit). The serum level of Pharmacia-CDT was significantly higher in the patients with alcoholic liver disease (38.9 +/- 2.8 U/l) compared to the normal subjects (18.9 +/- 0.2 U/l), alcoholics without liver disease (21.7 +/- 1.5 U/l) and non-alcoholic liver disease (viral liver disease) (23.4 +/- 1.6 U/l) (P < 0.001). The serum level of Axis-CDT was also significantly higher in the patients with alcoholic liver disease (4.22 +/- 0.48%) compared to the normal subjects (0.84 +/- 0.14%), alcoholics without liver disease (1.14 +/- 0.23%) and non-alcoholic liver disease (1.84 +/- 0.29%) (P < 0.001).

A significant correlation was found between serum levels of CDT **determined** by the two kits (r = 0.718, P < 0.001). The serum level of Axis-CDT was significantly higher in patients with alcoholic hepatitis compared to the normal subjects (P < 0.005), while the serum level of Pharmacia-CDT was not increased in the patients with alcoholic hepatitis. These results indicate that **determination** of serum CDT levels is a useful marker of alcoholic liver disease, not a marker for **alcohol consumption**. Axis-CDT is more useful than Pharmacia-CDT for assaying the serum level of CDT in patients with alcoholic liver disease.

L138 ANSWER 10 OF 10 MEDLINE DUPLICATE 7  
93039033 Document Number: 93039033. Measurement of **carbohydrate-deficient transferrin** by isoelectric focusing/western blotting and by micro anion-exchange **chromatography** /radioimmunoassay: comparison of diagnostic accuracy. Xin Y; Rosman A S; Lasker J M; Lieber C S. (Alcohol Research & Treatment Center, Bronx Veterans Affairs Medical Center, NY. ) ALCOHOL AND ALCOHOLISM, (1992 Jul) 27 (4) 425-33. Journal code: AAL. ISSN: 0735-0414. Pub. country:

ENGLAND:  
United Kingdom. Language: English.

AB At present, the most reliable marker of recent and heavy alcohol intake is **carbohydrate-deficient transferrin** (CDT). While most CDT quantitation **methods** (including immunofixation and micro anion-exchange **chromatography** [MAEC] combined with radioimmunoassay [RIA]) either lack the precision required for diagnostic usage or are not commercially available, we recently described an isoelectric focusing/Western blotting (IEF/WB) procedure that provides sensitive and specific assessment of serum CDT content. However, a modified MAEC/RIA kit, supposedly more reliable than the original, is also being advanced as suitable for widespread clinical application. Therefore, we compared this modified MAEC/RIA procedure to the IEF/WB **method** of CDT quantitation in the following 108 subjects; 53 alcoholics undergoing detoxification without clinical or histological evidence of liver disease, 24 recently drinking alcoholics

Prepared by M. Hale 308-4258 Page 30

with biopsy-proven liver disease, eight alcoholics abstinent for more than 30 days with biopsy-proven liver disease, seven non-drinking patients with non-alcoholic liver disease, and 16 healthy controls. Although CDT measurements by the two **methods** were correlated ( $r = 0.60$ ,  $P < 0.01$ ), serum CDT values obtained with IEF/WB were nearly five-fold higher than those obtained with MAEC/RIA (e.g.  $140.0 \pm 58$  versus  $28.5 \pm 16$  mg/l among the active drinkers). Of the two **methods**, IEF/WB exhibited significantly greater sensitivity than MAEC/RIA for detecting recent, heavy drinking (75% versus 61%,  $P < 0.05$ ) and generated no false positives whereas MAEC/RIA gave falsely elevated CDT levels in 37% of the abstinent alcoholics. (ABSTRACT. TRUNCATED AT 250 WORDS)

```
L139      20 FILE MEDLINE
L140      19 FILE CAPLUS
L141       9 FILE BIOSIS
L142     17 FILE EMBASE
L143       1 FILE WPIDS
L144       0 FILE JICST-EPLUS
```

```
TOTAL FOR ALL FILES
L145      66 L109 AND ASSAY
```

```
=> s sundrehagen e?/au,in and l145
```

```
'IN' IS NOT A VALID FIELD CODE
L146       0 FILE MEDLINE
L147       0 FILE CAPLUS
L148       1 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L149       0 FILE EMBASE
L150       1 FILE WPIDS
L151       0 FILE JICST-EPLUS
```

```
TOTAL FOR ALL FILES
L152       2 SUNDREHAGEN E?/AU,IN AND L145
```

```
=> dup rem l152
```

```
PROCESSING COMPLETED FOR L152
L153       2 DUP REM L152 (0 DUPLICATES REMOVED)
```

```
=> d 1-2 cbib abs
```

```
L153 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2000 BIOSIS
1997:375425 Document No.: PREV199799674628. Semiautomated carbohydrate
-deficient transferrin for the diagnosis of alcohol
abuse. Bean, P. (1); Liegmann, K.; Sundrehagen, E.. (1)
Specialty Lab., Santa Monica, CA USA. Alcoholism Clinical and
Experimental
Research, (1997) Vol. 21, No. 3, pp. 29A. Meeting Info.: Annual
Scientific
```



L153 ANSWER 2 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD

AN 1996-402495 [40] WPIDS

AB WO 9626444 A UPAB: 19961007

**Method** for assessment of carbohydrate-deficient transferrin (CDTF) in a transferrin (TF) contg. **body fluid**, comprises:

- (a) obtaining a TF contg. liq. sample of or derived from the fluid,
- (b) contacting the sample with a source of iron ions,
- (c) contacting the sample with an anionic ion exchange resin at a pH so as to cause CDTF to be retained by the resin,
- (d) contacting the resin with an eluant to release the CDTF into the eluate,
- (e) collecting a vol. of the eluate, free from tetra- and

penta-sialo  
TF and

- (f) assessing the TF variant content in the vol. of eluate.

Also claimed are:

- (1) a kit for a diagnostic **assay** for CDTF, comprising: (a') an iron ion contg. buffered incubation soln. having a pH of 6.2,
- (b') opt. a TF soln. of known concn.,
- (c') an anionic ion exchange resin packed in a container having sample introduction and eluate removal ports,
- (d') opt. a flushing eluant having a pH and ionic strength insufficient to release TF from the resin,
- (e') a release eluant having a pH and ionic strength sufficient to release TF from the resin,

- (f') opt. a light transmitting eluate receiving vessel,

- (g') opt. an anti-TF antibody or fragment and

- (h') opt. an opacification enhancer;

- (2) a **method** for assaying for alcohol consumption, comprising assessing a **blood derived body fluid** sample for its content of a de-sialo TF, characterised in that the de-sialo TF comprises tri-sialo TF and opt. 1 of di-sialo, mono-sialo and a sialo TF;

- (3) a **method** for assaying for alcohol consumption, comprising:

- (a'') obtaining a first TF contg. liq. sample of or derived from a **body fluid** and contg. tetra- and penta-sialo TFs,

- (b'') obtaining from the first sample a second TF contg. liq. sample which is free from tetra- and penta-sialo TF and having a TF content of

1

mg/l and

- (c'') turbidimetrically assessing the TF content of the second sample.

USE - The **method** is used for the **assay** of CDTF as an effective marker for alcohol consumption, in partic. for detecting and monitoring chronic alcohol consumption.

ADVANTAGE - Using the **method**, CDTF levels can be assessed using simple measurement techniques such as turbidimetry without needing signal amplification steps and while requiring only small **body fluid** samples.

Dwg.0/7

=> d 2

L153 ANSWER 2 OF 2 WPIDS COPYRIGHT 2000 DERWENT INFORMATION LTD  
AN 1996-402495 [40] WPIDS  
DNN N1996-339049 DNC C1996-126591  
TI **Carbohydrate-deficient transferrin**  
assay - using anionic ion exchange resin, used for assaying for  
alcohol consumption.  
DC B04 S03  
IN **SUNDREHAGEN, E**  
PA (AXIS-N) AXIS BIOCHEMICALS AS; (COCK-I) COCKBAIN J; (AXIS-N) AXIS-SHIELD  
ASA  
CYC 71  
PI WO 9626444 A1 19960829 (199640)\* EN 44p G01N033-68  
RW: AT BE CH DE DK EA ES FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE  
SZ UG  
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS  
JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT  
RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN  
AU 9647270 A 19960911 (199651) G01N033-68  
NO 9703844 A 19971021 (199802) G01N033-68  
EP 811166 A1 19971210 (199803) EN G01N033-68  
R: AT BE CH DE DK ES FR GB GR IE IT LI NL SE  
FI 9703432 A 19971017 (199804) G01N000-00  
EP 854363 A1 19980722 (199833) EN G01N033-68  
R: AT BE CH DE DK ES FR GB GR IE IT LI NL SE  
US 5798212 A 19980825 (199841) G01N033-53  
JP 11500227 W 19990106 (199911) 45p G01N033-68  
AU 708780 B 19990812 (199944) G01N033-68  
EP 811166 B1 19991006 (199946) EN G01N033-68  
R: AT BE CH DE DK ES FR GB GR IE IT LI NL SE  
DE 69604567 E 19991111 (199954) G01N033-68  
ES 2140064 T3 20000216 (200016) G01N033-68  
US 6103478 A 20000815 (200041) G01N033-53  
ADT WO 9626444 A1 WO 1996-GB395 19960221; AU 9647270 A AU 1996-47270  
19960221;  
NO 9703844 A WO 1996-GB395 19960221, NO 1997-3844 19970821; EP 811166 A1  
EP 1996-903125 19960221, WO 1996-GB395 19960221; FI 9703432 A WO  
1996-GB395 19960221, FI 1997-3432 19970821; EP 854363 A1 Div ex EP  
1996-903125 19960221, EP 1998-200650 19960221; US 5798212 A Cont of WO  
1996-GB395 19960221, US 1996-716913 19960909; JP 11500227 W JP  
1996-525494  
19960221, WO 1996-GB395 19960221; AU 708780 B AU 1996-47270 19960221; EP  
811166 B1 EP 1996-903125 19960221, WO 1996-GB395 19960221, Related to EP  
1998-200650 19960221; DE 69604567 E DE 1996-604567 19960221, EP  
1996-903125 19960221, WO 1996-GB395 19960221; ES 2140064 T3 EP  
1996-903125  
19960221; US 6103478 A CIP of WO 1996-GB395 19960221, Div ex US  
1996-716913 19960909, US 1998-26156 19980219  
FDT AU 9647270 A Based on WO 9626444; EP 811166 A1 Based on WO 9626444; EP  
854363 A1 Div ex EP 811166; JP 11500227 W Based on WO 9626444; AU 708780  
B  
Previous Publ. AU 9647270, Based on WO 9626444; EP 811166 B1 Related to  
EP

854363, Based on WO 9626444; DE 69604567 E Based on EP 811166, Based on  
 WO 9626444; ES 2140064 T3 Based on EP 811166; US 6103478 A Div ex US 5798212  
 PRAI GB 1995-16885 19950817; GB 1995-3484 19950222; GB 1995-6045  
 19950324  
 IC ICM G01N000-00; G01N033-53; G01N033-68  
 ICS G01N033-48; G01N033-543; G01N033-563; G01N033-98

=> dis his

(FILE 'HOME' ENTERED AT 10:23:45 ON 13 SEP 2000)

FILE 'REGISTRY' ENTERED AT 10:24:17 ON 13 SEP 2000  
 E TRANSFERRIN/CN 5  
 E CARBOHYDRATE FREE TRANSFERRIN/CN 5  
 L1 443 S ?TRANSFERRIN?/CNS

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, WPIDS, JICST-EPLUS' ENTERED AT  
 10:25:24 ON 13 SEP 2000  
 L2 411 FILE MEDLINE  
 L3 208 FILE CAPLUS  
 L4 331 FILE BIOSIS  
 L5 427 FILE EMBASE  
 L6 15 FILE WPIDS  
 L7 4 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L8 1396 S (L1 OR ?TRANSFERRIN? OR SIDEROPHILIN? OR  
 (D12.775.124.50.800  
 L9 0 FILE MEDLINE  
 L10 2 FILE CAPLUS  
 L11 0 FILE BIOSIS  
 L12 0 FILE EMBASE  
 L13 2 FILE WPIDS  
 L14 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L15 4 S L8(10A)CARBOHYDRATE FREE  
 L16 2 DUP REM L15 (2 DUPLICATES REMOVED)  
 L17 260 FILE MEDLINE  
 L18 145 FILE CAPLUS  
 L19 245 FILE BIOSIS  
 L20 251 FILE EMBASE  
 L21 6 FILE WPIDS  
 L22 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L23 908 S L8(10A)CARBOHYDRATE DEFICIEN?  
 L24 376 FILE MEDLINE  
 L25 236 FILE CAPLUS  
 L26 459 FILE BIOSIS  
 L27 382 FILE EMBASE  
 L28 8 FILE WPIDS  
 L29 25 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L30 1486 S (CARBOHYDRATE(W) (FREE OR DEFICIEN?)) (5A) (L1 OR  
 ?TRANSFERRIN?

Prepared by M. Hale 308-4258

Page 34

L31 260 FILE MEDLINE  
 L32 145 FILE CAPLUS  
 L33 245 FILE BIOSIS  
 L34 251 FILE EMBASE  
 L35 3 FILE WPIDS  
 L36 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L37 905 S L30(10A) (ALCOHOLISM OR ALCOHOL(2A) (CONSUMP? OR DRINK?) OR  
 TEM  
 L38 8 FILE MEDLINE  
 L39 14 FILE CAPLUS  
 L40 7 FILE BIOSIS  
 L41 6 FILE EMBASE  
 L42 0 FILE WPIDS  
 L43 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L44 35 S L37 AND (ASIALO OR MONOSIALO OR TRISIALO OR TETRASIALO OR  
 PEN  
 L45 8 FILE MEDLINE  
 L46 13 FILE CAPLUS  
 L47 7 FILE BIOSIS  
 L48 6 FILE EMBASE  
 L49 0 FILE WPIDS  
 L50 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L51 34 S L44 NOT L15  
 L52 15 DUP REM L51 (19 DUPLICATES REMOVED)  
 L53 252 FILE MEDLINE  
 L54 131 FILE CAPLUS  
 L55 238 FILE BIOSIS  
 L56 245 FILE EMBASE  
 L57 3 FILE WPIDS  
 L58 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L59 870 S L37 NOT L44  
 L60 252 FILE MEDLINE  
 L61 130 FILE CAPLUS  
 L62 238 FILE BIOSIS  
 L63 245 FILE EMBASE  
 L64 1 FILE WPIDS  
 L65 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L66 867 S L59 NOT L15  
 L67 4 FILE MEDLINE  
 L68 2 FILE CAPLUS  
 L69 2 FILE BIOSIS  
 L70 1 FILE EMBASE  
 L71 0 FILE WPIDS  
 L72 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L73 9 S L66 AND (BIND? LIGAND OR LECTIN?)  
 L74 6 DUP REM L73 (3 DUPLICATES REMOVED)  
 L75 248 FILE MEDLINE  
 L76 128 FILE CAPLUS  
 L77 236 FILE BIOSIS  
 L78 244 FILE EMBASE

L79 1 FILE WPIDS  
 L80 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L81 858 S L66 NOT L73  
 L82 0 FILE MEDLINE  
 L83 0 FILE CAPLUS  
 L84 0 FILE BIOSIS  
 L85 0 FILE EMBASE  
 L86 0 FILE WPIDS  
 L87 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L88 0 S (SAMBUC? OR MAACK? OR ESCHERCHIA OR HELICOBACTER OR RICIN?  
 OR  
 L89 224 FILE MEDLINE  
 L90 79 FILE CAPLUS  
 L91 87 FILE BIOSIS  
 L92 132 FILE EMBASE  
 L93 1 FILE WPIDS  
 L94 1 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L95 524 S L81 AND BLOOD  
 L96 0 FILE MEDLINE  
 L97 2 FILE CAPLUS  
 L98 1 FILE BIOSIS  
 L99 0 FILE EMBASE  
 L100 1 FILE WPIDS  
 L101 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L102 4 S L81 AND BODY FLUID  
 L103 109 FILE MEDLINE  
 L104 49 FILE CAPLUS  
 L105 57 FILE BIOSIS  
 L106 68 FILE EMBASE  
 L107 1 FILE WPIDS  
 L108 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L109 284 S (L95 OR L102) AND (DETERM? OR DETM OR METHOD)  
 L110 31 FILE MEDLINE  
 L111 18 FILE CAPLUS  
 L112 14 FILE BIOSIS  
 L113 19 FILE EMBASE  
 L114 0 FILE WPIDS  
 L115 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L116 82 S L109 AND (SEPARAT? OR PRECIPIT? OR CENTRIFUG? OR FILT? OR  
 CHR  
 L117 1 FILE MEDLINE  
 L118 1 FILE CAPLUS  
 L119 0 FILE BIOSIS  
 L120 1 FILE EMBASE  
 L121 0 FILE WPIDS  
 L122 0 FILE JICST-EPLUS  
 TOTAL FOR ALL FILES  
 L123 3 S L116 AND (TURBIDOMET? OR NEPHELOMET?)  
 L124 7 FILE MEDLINE  
 L125 2 FILE CAPLUS

```

L126          5 FILE BIOSIS
L127          5 FILE EMBASE
L128          0 FILE WPIDS
L129          0 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L130          19 S L116 AND KIT
L131          8 FILE MEDLINE
L132          3 FILE CAPLUS
L133          5 FILE BIOSIS
L134          6 FILE EMBASE
L135          0 FILE WPIDS
L136          0 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L137          22 S L123 OR L130
L138          10 DUP REM L137 (12 DUPLICATES REMOVED)
L139          20 FILE MEDLINE
L140          19 FILE CAPLUS
L141          9 FILE BIOSIS
L142          17 FILE EMBASE
L143          1 FILE WPIDS
L144          0 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L145          66 S L109 AND ASSAY
L146          0 FILE MEDLINE
L147          0 FILE CAPLUS
L148          1 FILE BIOSIS
L149          0 FILE EMBASE
L150          1 FILE WPIDS
L151          0 FILE JICST-EPLUS
TOTAL FOR ALL FILES
L152          2 S SUNDREHAGEN E?/AU,IN AND L145
L153          2 DUP REM L152 (0 DUPLICATES REMOVED)

=> s l145 not (l152 or l130 or l123 or l73 or l44 or l15)

L154          17 FILE MEDLINE
L155          17 FILE CAPLUS
L156          6 FILE BIOSIS
L157          16 FILE EMBASE
L158          0 FILE WPIDS
L159          0 FILE JICST-EPLUS

TOTAL FOR ALL FILES
L160          56 L145 NOT (L152 OR L130 OR L123 OR L73 OR L44 OR L15)

=> dup rem l160

PROCESSING COMPLETED FOR L160
L161          32 DUP REM L160 (24 DUPLICATES REMOVED)

=> d cbib abs 1-32

```

```

L161 ANSWER 1 OF 32 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
2000198926 EMBASE [Carbohydrate deficient
transferrin, the use as marker for alcohol abuse].
Prepared by M. Hale 308-4258

```

KOOLHYDRAATDEFICIENT **TRANSFERRINE**: BETEKENIS ALS MARKER VOOR ALCOHOLMISBRUIK. Kreutzer H.J.H.; Van Pelt J.. Dr. H.J.H. Kreutzer, Vinkelsestraat 163, 5382 JA Vinkel, Netherlands. Nederlands Tijdschrift voor de Klinische Chemie 25/3 (166-169) 2000.

Refs: 31.

ISSN: 1380-3689. CODEN: NTKCFX. Pub. Country: Netherlands. Language: Dutch. Summary Language: English; Dutch.

AB There is a urgent need for tests that can detect chronic alcohol abuse. Several studies are published on the influence of high ethanol intake on the reduced glycosylation of **transferrin**, resulting in **carbohydrate-deficient transferrin**.

**Methods** for the separation of **carbohydrate-deficient transferrin** involve either iso-electric focussing or ion exchange chromatography. The latter principle is used

for routine **assays** with automated equipment for the **transferrin determination**. Possibly, the percentage of the deficient isoforms to the total **transferrin** amount is less susceptible to variations in the total **transferrin** concentration as the absolute concentration of **carbohydrate-deficient transferrin**. The CDT test, in combination with the GGT, has a very high specificity and the sensitivity is acceptable merely when the test

is used for patients with serious suspicion of alcohol abuse. In other cases, up to 50% false negatives can be detected.

L161 ANSWER 2 OF 32 MEDLINE

2000203534 Document Number: 20203534. Stability of **carbohydrate deficient transferrin** (CDT) in stored **blood** samples. Kohler H; West A; Brinkmann B. (Institute of Legal Medicine, Westfalische Wilhelms-Universitat, Munster, Germany.. kohlerh@uni-muenster.de) . INTERNATIONAL JOURNAL OF LEGAL MEDICINE, (2000) 113 (2) 121-2. Journal code: AX1. ISSN: 0937-9827. Pub. country: GERMANY: Germany, Federal Republic of. Language: English.

AB The **alcoholism** marker CDT was **determined** on 257 **blood** samples 1-2 days after the **blood** samples were taken and again after storage for 7 months at +4 degrees C. The differences between the pairs of CDT values were so large that the **determination** of CDT after long term storage of the **blood** sample has no evidential value.

L161 ANSWER 3 OF 32 MEDLINE

DUPLICATE 1

2000016185 Document Number: 20016185. Relative versus absolute **carbohydrate-deficient transferrin** as a marker of **alcohol consumption** in patients with acute alcoholic hepatitis. Halm U; Tannapfel A; Mossner J; Berr F. (Department of Medicine II, University of Leipzig, Germany.. halmu@medizin.uni-leipzig.de) . ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH, (1999 Oct) 23 (10) 1614-8. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB **BACKGROUND**: **Carbohydrate-deficient transferrin** has been described as a sensitive and specific marker for **alcohol consumption**. This study investigated the usefulness of **carbohydrate-deficient transferrin** as a marker of **alcohol consumption** in acute alcoholic hepatitis.

**METHODS**: Absolute concentrations (U/I) and relative values (%) of  
Prepared by M. Hale 308-4258 Page 38

**carbohydrate-deficient transferrin** determined in serum with commercial assays, as well as conventional markers for **alcohol consumption**, were compared with the **alcohol consumption** (as estimated by a questionnaire) in patients with acute alcoholic hepatitis (n = 19), alcoholic liver cirrhosis (n = 37), and nonalcoholic liver diseases (n = 16). RESULTS: The concentration of **carbohydrate-deficient transferrin** was increased ( $p < 0.001$ ) in nonabstaining patients (median intake 80 g alcohol/day) with alcoholic liver cirrhosis ( $45.7 \pm 30$  U/l), but not in patients with acute alcoholic hepatitis ( $20.0 \pm 7.8$  U/l) despite higher **alcohol consumption** (median 130 g/d), nor in abstainers with alcoholic liver cirrhosis ( $19.4 \pm 6.0$  U/l) or nonalcoholic liver disease (18.5

+/-

6.7 U/l). However, the relative values of **carbohydrate-deficient transferrin** were increased both in acute alcoholic hepatitis ( $7.9 \pm 2.1\%$ ) and nonabstainers with alcoholic liver cirrhosis ( $7.4 \pm 2.8\%$ ), but not in abstainers with alcoholic liver cirrhosis ( $4.6 \pm 3.5\%$ ) or nonalcoholic liver disease ( $3.8 \pm 0.9\%$ ) ( $p$

<

0.001). In acute alcoholic hepatitis, the sensitivity and specificity were

only 32% and 87% for absolute concentrations, respectively, but 79% and 97% for relative values of **carbohydrate-deficient transferrin**. The concentrations of **carbohydrate-deficient** and total **transferrin** in serum were strongly correlated ( $r = 0.60$ ;  $p = 0.008$ ). CONCLUSIONS: The relative value (% of total), but not the absolute concentration, of **carbohydrate-deficient transferrin** in serum is a useful marker of **alcohol consumption** in acute alcoholic hepatitis.

L161 ANSWER 4 OF 32 MEDLINE

1999323417 Document Number: 99323417. Sialic acid: new potential marker of alcohol abuse. Sillanaukee P; Ponnio M; Seppa K. (Pharmacia & Upjohn AB Diagnostics, Alcohol Related Diseases, Uppsala, Sweden.. pekka.sillanaukee@sci.fi) . ALCOHOLISM, CLINICAL AND EXPERIMENTAL

RESEARCH,

(1999 Jun) 23 (6) 1039-43. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB BACKGROUND: A number of laboratory markers are suggested for the detection

and monitoring of alcohol abuse. However, there is still a need to find better indicators of alcohol abuse. Sialic acid (SA) is the name for a series of acyl-derivatives of neuraminic acids that occur as nonreducing terminal residues of glycoproteins or glycolipids in biological fluids

and

cell membranes. In this study, we investigated the diagnostic value of SA as a marker of alcohol abuse. METHODS: Sera from social drinkers (n = 38) and alcoholics (n = 77) were analyzed for sialic acid by a colorimetric assay and for **carbohydrate-deficient transferrin** (CDT) by a radioimmunoassay method. Mean corpuscular volume (MCV), gamma-glutamyltransferase (GGT), aspartate aminotransferase (ASAT), and alanine aminotransferase (ALAT) were determined by using routine methods.

RESULTS: The sialic acid levels of both female and male subjects were significantly ( $p < 0.001$ ) increased among alcoholic subjects when

compared

Prepared by M. Hale 308-4258

Page 39



with social drinkers. SA levels were decreased after 3 weeks of treatment.

The sensitivity and specificity for SA, respectively, were 57.7 and 95.5 for women and 47.8 and 81.3 for men. The respective values for CDT were 57.7 and 95.5 for women and 78.3 and 100.0 for men; for GGT, 60.0 and 95.5 for women and 60.9 and 87.5 for men; for MCV, 52.4 and 95.5 for women and 47.8 and 100.0 for men; for ASAT, 53.8 and 95.5 for women and 43.5 and 100.0 for men; and for ALAT, 38.5 and 90.9 for women and 39.1 and 87.5 for

men. Among women, SA and GGT, and among men CDT, showed the largest area under receiver operation curve. CONCLUSION: This study indicated that sialic acid levels were elevated by high alcohol consumption and reduced during abstinence, especially among women. Thus, sialic acid seems to be an interesting marker that needs further evaluation as a diagnostic tool for alcohol abuse.

L161 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 2  
1999:646163 Document No. 131:282645 Evaluation of the cut-off for serum **carbohydrate-deficient transferrin** as a marker of chronic alcohol abuse determined by the ChronAlco I.D. TM-assay. Arndt, Torsten; Behnken, L. J.; Martens, B.; Hackel, R. (Institut Laboruntersuchungen Ingelheim G.m.b.H., Ingelheim, D-55218, Germany). Laboratoriumsmedizin, 23(9), 507-510 (English) 1999. CODEN: LABOD3. ISSN: 0342-3026. Publisher: Blackwell Wissenschafts-Verlag

GmbH.

AB The aim of the study was to establish reliable cut-off values, indicating chronic alc. abuse, of the relative (and abs.) serum **carbohydrate-deficient transferrin** (CDT) concns. detd. by the ChronAlco I.D.-assay. Serum samples from 88 women and 48 men, with the daily alc. consumption, acute or chronic (liver) diseases and medication ascertained by means of a questionnaire, were analyzed. The cut-off values of the CDT/transferrin ratios and the CDT serum concns. (95th percentiles) for women consuming < 20 g ethanol/day and men drinking < 50 g ethanol/day were 2.5% and 102 mg/L. Pathol. CDT results were confirmed by isoelec. focusing. Taking into account the intra-individual variance of serum CDT and the anal. imprecision, the use of a borderline of 2.5-2.7% as decision criterion indicating chronic alc. abuse is suggested.

L161 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 3  
1999:482396 Document No. 131:127336 Relative and absolute CDT concentrations in sera from anemic patients measured by commercial immunoassays following miniaturized column chromatography and by high performance liquid chromatography. Niemeier, Anja; Blocker, Kathrin; Dibbelt, Leif (Inst. Klinische Chem., Med. Univ. Lubeck, Lubeck, D-23538, Germany). Clin.

Lab.

(Heidelberg), 45(7/8), 371-376 (English) 1999. CODEN: CLLAFP.

Publisher:

Clin Lab Publications.

AB Detn. of **carbohydrate-deficient transferrin** (CDT) is frequently used as a lab. tool for the diagnosis and follow-up of chronically increased alc. consumption. To study the effect of iron deficiency anemia on CDT

Prepared by M. Hale 308-4258

Page 40

concns., 200 sera from patients presenting with decreased Hb and ferritin levels were analyzed for relative CDT concn. using the new Tina-quant %CDT immunoturbidimetric **assay** on a Hitachi 717 analyzer (Roche Diagnostics). The results were compared to abs. CDT concns. obtained with an established CDT RIA (CDTect, Pharmacia & Upjohn) and to relative CDT concns. **detd.** by high performance liq. chromatog. (HPLC) in the same sera. The data measured with the three **methods** show only a weak correlation (correlation coeffs. < 0.5), apparently not only due to a difference between abs. and relative CDT concns. but also to the fact that different patterns of hyposialylated **isotransferrins** are detected by the various **assays**. No sample exhibited increased CDT concn. when assayed by HPLC indicating that iron deficiency anemia does not cause marked changes in **transferrin** glycan compn. When the abs. CDT concn. was measured by the CDTect RIA it was slightly to markedly increased in 54 of the 200 sera tested. The Tina-quant %CDT **assay**, however, yielded relative CDT concns. above the decision limit for chronically increased **alc. consumption** in only 5 sera.

L161 ANSWER 7 OF 32 BIOSIS COPYRIGHT 2000 BIOSIS  
2000:54456 Document No.: PREV200000054456. Limitations of CDT and GGT in detecting relapses in patients attending an alcohol problems clinic. Limin, S.; Jarvie, D. R.; Chick, J. (1); Simpson, D.. (1) Alcohol

Problems  
Clinic, 35 Morningside Park, Edinburgh, EH10 5HD UK. Scottish Medical Journal, (Oct., 1999) Vol. 44, No. 5, pp. 140-142. ISSN: 0036-9330. Language: English. Summary Language: English.

AB Biochemical markers of **alcohol consumption** are useful for the detection and monitoring of problem drinking. **Blood** samples from 37 patients attending an alcohol treatment clinic were analysed for GGT and %CDT, and results were compared with self-reported periods of abstinence and **alcohol consumption**. Poor correlation was obtained between GGT and %CDT, and between these **assays** and self-reported alcohol use. The apparent sensitivity and specificity of GGT (57%, 63%) and %CDT (43%, 88%), were considerably lower than those reported by other workers.

L161 ANSWER 8 OF 32 MEDLINE DUPLICATE 4  
1999113048 Document Number: 99113048. Absolute or relative measurement of **carbohydrate-deficient transferrin** in serum? Experiences with three immunological **assays**. Helander A. (Karolinska Institutet, Departments of Clinical Neuroscience and Clinical Chemistry, Alcohol and Drug Dependence Unit at Karolinska Hospital, SE-17176 Stockholm, Sweden.. anders.helander@bekl.csso.sll.se) . CLINICAL CHEMISTRY, (1999 Jan) 45 (1) 131-5. Journal code: DBZ. ISSN: 0009-9147. Pub. country: United States. Language: English.

L161 ANSWER 9 OF 32 MEDLINE DUPLICATE 5  
1998432388 Document Number: 98432388. Intra- and interindividual variability of **carbohydrate-deficient transferrin**.

gamma-glutamyltransferase, and mean corpuscular volume in teetotalers.  
Helander A; Vabo E; Levin K; Borg S. (Department of Clinical  
Neuroscience,

Karolinska Institute, Center for Dependency Disorders at St. Gorans &  
Karolinska Hospital, Stockholm, Sweden...  
anders.helander@bekl.csso.sll.se)

. CLINICAL CHEMISTRY, (1998 Oct) 44 (10) 2120-5. Journal code: DBZ.

ISSN:

0009-9147. Pub. country: United States. Language: English.

AB **Blood samples for determination of the biochemical**  
**alcohol markers carbohydrate-deficient**  
**transferrin** (CDT) in serum, gamma-glutamyltransferase (GGT) in  
serum, and erythrocyte mean corpuscular volume (MCV) were collected once  
every 1-2 weeks over approximately 5 months from 10 female and 4 male  
teetotalers. Mean values for serum CDT (using the CDTest **assay**)  
ranged from 9.9 to 29.4 units/L (median, 14.2 units/L), and the highest  
results were obtained in the women. The mean values for serum GGT ranged  
from 0.15 to 0.49 microkat/L (median, 0.30 microkat/L, or 18 U/L) except  
for one woman with a very high mean of 3.07 microkat/L. For MCV, the mean  
values ranged from 79.5 to 91.5 fL. Two women showed several CDT results  
above the upper reference limit (mean values, 27.6 and 29.4 units/L,  
respectively); however, their GGT and MCV values fell within the

reference

intervals. One of these women exhibited an increased total  
**transferrin** concentration (mean value, 5.38 g/L), which was  
possibly related to the use of oral contraceptives and/or a low serum

iron

concentration. When the CDTest value was expressed relative to total  
**transferrin**, a ratio within the reference interval was observed  
for this woman but not for the other woman with increased CDTest values.  
The present study demonstrates a considerable variation between  
individuals in CDT, GGT, and MCV without **drinking any**  
**alcohol**. The results also show that these baseline values are  
fairly constant over time within the same individual.

L161 ANSWER 10 OF 32 MEDLINE

1999050964 Document Number: 99050964. **Carbohydrate-**  
**deficient transferrin**: diagnostic efficiency among  
patients with end-stage liver disease before and after liver  
transplantation. Heinemann A; Sterneck M; Kuhlencordt R; Rogiers X;

Schulz

K H; Queen B; Wischhusen F; Puschel K. (Institute of Legal Medicine,  
University Hospital Hamburg, Germany. ) ALCOHOLISM, CLINICAL AND  
EXPERIMENTAL RESEARCH, (1998 Nov) 22 (8) 1806-12. Journal code: 35X.  
ISSN: 0145-6008. Pub. country: United States. Language: English.

AB We tested the diagnostic validity of **carbohydrate-**  
**deficient transferrin** (CDT) as an indicator for relapse  
into elevated **alcohol consumption** among patients who  
were examined under follow-up treatment before (n = 147) and after (n =  
102) orthotopic liver transplantation (OLT) in the outpatient-department  
of the University Hospital Department of Surgery in Hamburg-Eppendorf.

CDT

measurements were performed with two commercial kits in parallel  
(CDTest-RIA and CDT%-RIA). Short-term parameters of **alcohol**  
**consumption** (ethanol, methanol) indicated relapses into elevated  
**alcohol consumption** in 11.4% of the evaluated patients

Prepared by M. Hale 308-4258

Page 42

with alcoholic liver disease (ALD) before transplantation. Before OLT, median CDT values were **determined** to be elevated among patients with alcoholic as well as nonalcoholic end-stage liver diseases (NALD). Among patients with ALD, we found elevated CDT medians even in those who were successfully scheduled for OLT after long-term evidence of abstinence proved by biochemical short-term parameters and psychological tests. Both CDTest and CDT% **assays** had comparable low specificities in selected patient groups before transplantation. CDT% and CDTest were negatively correlated with the albumin level. Before the study ended, CDT was no longer implemented in the evaluation of whether an OLT should be administered. This was due to inconsistent results of CDT in ALD as well as NALD. After OLT, patients with ALD, as well as NALD, had statistically significant lower CDT medians than before OLT, which ranged within reference levels. We **determined**, according to CDT, elevated **alcohol consumption** subsequent to OLT in 4 of 13 patients with ALD who underwent transplantation during the study (median observation period: 10 months). CDT does not appear to be useful in evaluating patients before OLT. With regained specificity and high sensitivity in patients after OLT, CDT could be recommended as a standard instrument for quality control in patients with ALD after liver transplantation.

o

L161 ANSWER 11 OF 32 MEDLINE DUPLICATE 6  
 1998286708 Document Number: 98286708. Comparison of the Axis %CDT TIA and the CDTest **method** as laboratory tests of alcohol abuse. Viitala K; Lahdesmaki K; Niemela O. (EP Central Hospital Laboratory, Seinajoki, Finland. ) CLINICAL CHEMISTRY, (1998 Jun) 44 (6 Pt 1) 1209-15. Journal code: DBZ. ISSN: 0009-9147. Pub. country: United States. Language: English.

AB **Carbohydrate-deficient transferrin** (CDT) has been suggested as a specific marker of alcohol abuse. We designed this study to compare the conventional CDTest **method** (Pharmacia & Upjohn) and the new semiautomated Axis %CDT turbidimetric immunoassay (%CDT TIA) for their diagnostic performance to identify problem drinking. The sensitivities of the %CDT TIA and CDTest for correctly classifying heavy drinkers (n = 90) were 29% and 59% with the thresholds currently recommended by the manufacturers, respectively. In the control group (n = 114), which included hospitalized patients with abnormal serum **transferrin** concentrations, the CDTest **assay** gave 21 false-positive values (18%), whereas the %CDT TIA showed 100% specificity.

With the cutoff limits based on the present healthy control group (mean + 2 SD), the sensitivities of the %CDT TIA and CDTest were 61% and 86%, respectively. For men, the ROC plot area of the CDTest results in comparisons of alcohol abusers and healthy controls was significantly (P < 0.05) higher than that of the %CDT TIA results, whereas for women, there was no significant difference in this respect. The slope and intercept (with 95% confidence intervals) for linear regression between CDTest and %CDT TIA were 0.13 (0.12-0.15) and 1.16 (0.73-1.59), respectively (S(y/x) = 1.51, r = 0.744). CDTest results correlated positively with serum **transferrin** (r = 0.224, P < 0.001), whereas the %CDT TIA results showed a slight inverse correlation with serum **transferrin** (r = -0.132, P = 0.07). The data suggest that CDTest is more sensitive than %CDT TIA in detecting drinking problems. However, the %CDT TIA

Prepared by M. Hale 308-4258

method yields more specificity when analyzing samples from patients with high serum **transferrin** concentrations.

L161 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 7

1998:341157 Document No. 129:119850 **Carbohydrate deficient transferrin** in alcoholic and non-alcoholic liver disease: a comparison of two **assay methods**. Keating, James; Cheung, Connie; Peters, Timothy J.; Przemioslo, Robert; Williams, Roger; Sherwood, Roy A. (Department of Clinical Biochemistry, King's College School of Medicine and Dentistry, London, SE5 9PJ, UK). *Addict. Biol.*, 3(2), 205-211 (English) 1998. CODEN: ADBIFN. ISSN: 1355-6215. Publisher: Carfax Publishing Ltd..

AB **Carbohydrate-deficient transferrin** (CDT) was assayed in 105 patients with non-alc.-related liver diseases, 50 patients with alc.-induced liver disease and 40 alc. abusers with minimal hepatic dysfunction. The patients with liver disease were hospitalized for assessment of suitability for orthotopic liver transplantation. CDT was measured by two com. available micro anion exchange **methods**; CDTest (Pharmacia) and %CDT (AXIS). Addnl., total **transferrin** was measured to allow expression of the CDTest results as "relative" measurements. Overall, 41/105 (39%) of patients with non-alc.-related liver diseases had a raised CDTest result, 13/105 (12%) had a raised %CDT result and 26/105 (25%) an abnormal CDTest/total **transferrin** ratio. In general, patients with cholestatic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis had more "false pos." results by CDTest than did those with viral or autoimmune hepatitis. The sensitivity of the two **methods** for the detection of alc. misuse was similar; CDTest 77%, %CDT 65% and CDTest/total **transferrin** ratio 70%. This was, however, lower than the sensitivity of the conventional marker GGT (82%). In patients with severe liver disease, where up to 30% of the serum total **transferrin** concns. fall outside the ref. range, "relative" CDT **methods** have greater specificity than "abs." measurements.

L161 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 8

1998:323516 Document No. 128:318276 Examination of biochemical **alcoholism** parameters in **blood** samples of drivers under the influence of alcohol; with particular reference to **carbohydrate deficient transferrin**. Heinemann, Axel; Janke, Detlef; Pueschel, Klaus (Inst. Rechtsmedizin, Krankenhaus Eppendorf, Hamburg, D-22529, Germany). *Blutalkohol*, 35(3), 161-173 (German) 1998. CODEN: BLALAL. ISSN: 0006-5250. Publisher: Steintor-Verlag.

AB **Blood** samples of drunk driving offenders were examd. for sensitivity of current proceedings. Threshold values of **blood** alc. concn. (BAC, 1.6 or 2.0 .permill.) were analyzed by biochem. **alcoholism** parameters. MeOH, **carbohydrate deficient transferrin** (CDT%), and .gamma.-glutamyl transferase (GGT) were analyzed (group A: 1.1-1.59; B: 1.6-1.99; and C: >2.0 .permill.). Relevant groups of people in all 3 BAC categories fell within the normal range for markers of **alcoholism**. 24% In group B were inconspicuous, 68% in group A showed at least 1 elevation in parameter. The study emphasized a certain arbitrariness when choosing

BAC

indicator limits above 1.1 .permill.. Similar results to the ones achieved by CDT% **assay** were found using other **methods**

Prepared by M. Hale 308-4258

of CDT **detn.** Unlike to GGT, CDT% showed no dependency on age. An increasing no. of problematic values of GGT and CDT% was found in samples taken in the afternoon. For certain BAC areas no correlation was found between relative drinking symptomatics and GGT/CDT% measurements. The results were discussed with relevance to the altered legislation outline to exclude future scientific studies of similar concept.

L161 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2000 ACS DUPLICATE 9

1997:759931 Document No. 128:19448 **Determination of carbohydrate-deficient transferrin** and total **transferrin** by HPLC. Diagnostic evaluation. Renner, Florian; Stratmann, Karen; Kanitz, Rolf Dieter; Wetterling, Tilman (Inst.

Klinische

Chemie, Medizinische Univ. Luebeck, Luebeck, Germany). Clin. Lab. (Heidelberg), 43(11), 955-964 (English) 1997. CODEN: CLLAFP. Publisher: Clin Lab Publications.

AB The HPLC for **detn.** of **carbohydrate-deficient transferrin** (CDT) was compared with respect to its diagnostic validity with a com. **assay** (CDTect). Samples from alc. abusers characterized by alc. dependence and alc. withdrawal syndrome with elevated .gamma.-glutamyltransferase and mean corpuscular vol. of erythrocytes were analyzed by different **methods**. For males correlation between all **methods** was satisfactory, whereas for females the correlation between RIA and HPLC was low. Cut-off levels of 2.4% and 75 mg/L for relative and abs. HPLC measurements were calcd. The highest values for sensitivity, neg. predictive values and areas under

ROC

curves were obtained when the relative CDT values were **detd.** by HPLC. The **method** was suitable for simultaneous **detn.** of total **transferrin** concn.

L161 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2000 ACS

1997:560000 Document No. 127:231514 Comparison of two commercial test kits for quantification of serum **carbohydrate-deficient transferrin**. Stowell, L. I.; Fawcett, J. P.; Brooke, M.; Robinson, G. M.; Stanton, W. R. (Institute of Environmental Science and Research Ltd (ESR), Lower Hutt, N. Z.). Alcohol Alcohol. (Oxford),

32(4),

507-516 (English) 1997. CODEN: ALALDD. ISSN: 0735-0414. Publisher: Oxford University Press.

AB Serum levels of **carbohydrate-deficient**

**transferrin** (CDT) were measured in subjects of two independent studies using two different com. kits. The kits measure CDT either as a percentage of total **transferrin** (AXIS %CDT, AXIS Biochems. AS, Norway), or as the abs. amt. (CDTect, Pharmacia, Sweden). In a

population

of males (mean age 41 yr) consisting of alcoholics, heavy, moderate and non-drinkers, a strong correlation was found between AXIS %CDT and CDTect results ( $r = 0.92$ ,  $n = 58$ ,  $P < 0.001$ ). Sensitivity and specificity in detecting chronic alc. **drinking** of over 60 g/day were 78 and 94% for the AXIS **assay**, and 83 and 88% for the CDTect **assay**, resp. In a population from a birth cohort study, consisting of 21-yr-old males and females with less excessive alc. **consumption**, the correlation between AXIS %CDT and CDTect CDT was weaker but still statistically significant ( $r = 0.46$ ,  $n = 212$ ,  $P < 0.001$ ). In this population, with specificities  $>83\%$  in detecting

alc. consumption levels of .gtoreq.6 drinks per wk, the sensitivities were low with both CDT **assays** (<43% for .gtoreq.6 drinks per wk, and <44% for .gtoreq.16 drinks per wk). These results suggest that (a) both **assays** are equally effective in detecting chronic drinking over 60 g/day in older alc. males, and (b) both **assays** are similarly ineffective in detecting less excessive regular drinking in young males and females.

L161 ANSWER 16 OF 32 BIOSIS COPYRIGHT 2000 BIOSIS

1997:126837 Document No.: PREV199799418650. Increased serum concentration of **carbohydrate-deficient transferrin** in patients with combined pancreas and kidney transplantation. Arndt, Torsten (1); Hackler, Rolf; Mueller, Thomas; Kleine, Tilman O.; Gressner, Axel M.. (1) Institut fuer Laboruntersuchungen Ingelheim GmbH, Hamburger Str. 1, D-55218 Ingelheim Germany. Clinical Chemistry, (1997) Vol. 43, No. 2, pp. 344-351. ISSN: 0009-9147. Language: English.

AB Serum concentration of **carbohydrate-deficient transferrin** (cCDT) is used for laboratory diagnosis and follow-up of chronic alcohol abuse. In analyzing by CDTest-RIA (Pharmacia) sera from

outpatients with combined pancreas and kidney transplantation and no excessive **alcohol consumption**, we found above-normal values for cCDT and CDT/**transferrin** ratios (CDT/Tf) in more than half of the samples. Isoelectric focusing of these samples showed distinct

bands of **carbohydrate-deficient isotransferrins**, supporting the abnormal findings from the CDTest **assay**. In contrast, diabetics and outpatients who had received only kidney transplants showed normal values for cCDT, CDT/Tf, and **isotransferrin** patterns. Increased serum Tf, sialidase-producing microorganisms, and immunosuppressive medication were eliminated as causes

of these abnormal cCDT and CDT/Tf results. Successful pancreas transplantation leads to hyperinsulinemia and normoglycemia, in contrast to hypoinsulinemia and hyperglycemia in the patients who receive kidney transplants alone. These factors may have pathogenic importance for CDT increase, yielding results falsely interpreted as positive with respect

to alcohol abuse in patients with combined pancreas and kidney transplantation.

L161 ANSWER 17 OF 32 MEDLINE

97259387 Document Number: 97259387. Biochemical markers of alcohol use and abuse: experiences from the Pilot Study of the WHO/ISBRA Collaborative Project on state and trait markers of alcohol. International Society for Biomedical Research on **Alcoholism**. Helander A; Tabakoff B. (Karolinska Institute, Department of Clinical Neuroscience, St Gorans Hospital, Stockholm, Sweden. ) **ALCOHOL AND ALCOHOLISM**, (1997 Mar-Apr) 32 (2) 133-44. Journal code: AAL. ISSN: 0735-0414. Pub. country: ENGLAND: United Kingdom. Language: English.

AB The development of reliable diagnostic tools for assessing **alcoholism** and harmful **alcohol consumption** is an utmost necessity for the success of efforts to prevent and treat alcohol-induced damage to both individuals and to society. A

multinational

study is underway to aid in the development of biological screening tools

(state markers) which can, with good sensitivity and specificity, identify problem drinkers. To attain this goal information needs to be available on an individuals's drinking history and habits and related factors. A detailed instrument has been developed to obtain this information. The second goal of the study was to begin to develop diagnostic 'trait markers' which provide biological information on genetically **determined** predisposing and protective factors in the development of **alcoholism**. The developed questionnaire also provides background information on subject characteristics necessary for the development of trait markers. Centres will **assay** the obtained biological samples for 'traditional' and newly identified state markers of excessive **alcohol consumption**. These will include methanol measurements, gamma-glutamyltransferase, aspartate aminotransferase, **carbohydrate-deficient transferrin**, serotonin metabolite ratios, and erythrocyte aldehyde dehydrogenase. DNA obtained from the lymphocytes of subjects will be assayed for polymorphisms of alcohol- and aldehyde-metabolizing enzymes and dopamine receptor polymorphisms which can provide insights into protective and predisposing factors in **alcoholism**. The platelet enzymes, monoamine oxidase and adenylyl cyclase, will be assayed to assess the relationships between these putative trait markers and the genetic and environmental factors contributing to the aetiology of **alcoholism**. The current report is meant to introduce the study design and present a portion of the preliminary data gathered in the process of establishing this research programme.

L161 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2000 ACS

1997:172133 Document No. 127:77040 Clinical value of two **methods** for the **determination of carbohydrate-deficient transferrin**. Lyngbye, Jorgen; Eide, Arne; Walter, Henriette; Semler, Brigitte; Winkler, Franz; Lesch, Otto Michael (Department Clinical Chemistry, Molde Hospital, Molde, N-6400, Norway). Clin. Lab. (Heidelberg), 43(1+2), 53-55 (English) 1997. CODEN: CLLAFP. Publisher: Clin Lab Publications.

AB The routine **assays** CDTest and Axis%CDT RIA for the **detn** . of **carbohydrate-deficient transferrin** (CDT) and their use in monitoring alc. abuse were compared. The subjects investigated were divided into groups of comprised chronic alcoholics, social drinkers, total abstainers, and pregnant women. A correlation between **methods** and a specificity for alc. intake in all groups were demonstrated. CDT was elevated in 10.5% pregnant women without alc. intake by the CDTest **method** only. Both **methods** are well suited for monitoring alc. abuse.

L161 ANSWER 19 OF 32 MEDLINE

DUPLICATE 10

96330460 Document Number: 96330460. Sensitivity and specificity of **carbohydrate-deficient transferrin** as a marker of alcohol abuse are significantly influenced by alterations in serum **transferrin**: comparison of two **methods**. Sorvajarvi K; Blake J E; Israel Y; Niemela O. (EP Central Hospital Laboratory, Seinajoki, Finland. ) **ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH**, Prepared by M. Hale 308-4258

Page 47



(1996 May) 20 (3) 449-54. Journal code: 35X. ISSN: 0145-6008. Pub. country: United States. Language: English.

AB Despite a number of investigations suggesting the value of **carbohydrate-deficient transferrin** (CDT) as a marker of alcohol abuse, a variety of issues on the applicability of CDT measurements in clinical settings have remained unexplored. Earlier studies in this field have focused on the relationship of CDT and the amount of **alcohol consumption** or presence of liver disease, whereas the influence of alterations in serum **transferrin** concentrations on CDT has received less attention. In this study, we compared two different **methods** for measuring CDT (CDTect and %CDT) and total **transferrin** concentrations in a sample of 83 alcohol abusers (20 patients with alcoholic liver disease and 63 heavy drinkers who were devoid of liver disease, despite excessive **alcohol consumption**) and 89 controls, who were social drinkers or abstainers. The control population included 53 hospitalized patients with expected abnormalities in serum **transferrin** concentrations caused by conditions such as negative iron balance, pregnancy, or nonalcoholic liver disease. Both **methods** gave significantly higher values in alcohol abusers than in controls ( $p < 0.01$ ), but the overall sensitivity for detecting alcohol abuse was

clearly

higher for CDTect (59%) than for %CDT (34%). The correlation between the results obtained by the two **methods** ( $r = 0.629$ ) significantly improved, when the CDTect values were replaced by the ratio of CDTect/total **transferrin** ( $r = 0.770$ ) ( $p < 0.05$ ). There was a positive correlation between the CDTect and serum **transferrin** ( $r = 0.201$ ,  $p < 0.01$ ), which was significant both in the alcoholics ( $r = 0.240$ ,  $p < 0.05$ ), and especially in the controls ( $r = 0.727$ ,  $p < 0.001$ ).

A

significant inverse correlation emerged between %CDT and total **transferrin** ( $r = -0.302$ ,  $p < 0.01$ ). The sensitivities of CDTect and %CDT for correctly classifying alcohol abusers in the subgroup of alcoholic liver disease patients were 90% and 70% and in the subgroup of heavy drinkers without liver disease (49% and 22%), respectively. Specificities for CDTect and %CDT in this sample were 81% and 100%, respectively. However, in the subgroup of hospitalized control patients with abnormal serum **transferrin**, the specificity of CDTect was only 48%. According to present data, CDTect seems to be more sensitive than %CDT for detecting alcohol abuse. However, any alteration in serum total **transferrin** concentration markedly decreases the **assay** specificity. This should be considered when interpreting the **assay** results in patients with elevated serum **transferrin**, such as iron deficiency, pregnancy, or liver diseases.

L161 ANSWER 20 OF 32 BIOSIS COPYRIGHT 2000 BIOSIS

1996:263043 Document No.: PREV199698819172. Effect of cationic buffer additives on the capillary electrophoretic separation of serum **transferrin** from different species. Oda, Robert P.; Landers, James P. (1). (1) Clin. CE Fac., Dep. Lab. Med. Pathol., Hilton 920, Mayo

Clin.,

Rochester, MN 55905 USA. Electrophoresis, (1996) Vol. 17, No. 2, pp. 431-437. ISSN: 0173-0835. Language: English.

AB The presence of specific **transferrin** (Tf) glycoforms in human serum has been shown to correlate with certain clinical syndromes. Hence, the ability to separate and quantitatively measure the various forms of

Prepared by M. Hale 308-4258

Page 48

human **transferrin** has become increasingly important. As a means of evaluating the potential for developing a rapid capillary electrophoresis-based **assay** for the analysis of **carbohydrate-deficient transferrins** (CDTs), the capillary zone electrophoretic (CZE) analysis of Tfs from several species was evaluated using uncoated capillaries and a separation augmented with cationic additives. With bovine Tf, five peaks (representing different sialylated forms) were partially resolved in borate and baseline-resolved when 1,4-diaminobutane was added to the buffer. These same conditions were found to be inadequate for the resolution of the sialoforms from other species. Some success was achieved

using alpha,omega-bis-quaternary ammonium alkanes instead of the 1,4-diaminobutane and optimizing the pH for each of the species' Tfs.

Human

Tf was found to be resolved in an uncoated capillary equilibrated with a borate buffer containing millimolar concentrations of decamethonium bromide as a buffer additive. Under these conditions, resolution of the various sialoforms from the iron-saturated Tf was possible and the glycoforms were found to migrate differently than their iron-depleted counterparts. Despite the resolution achievable under these conditions, the lengthy analysis time is incompatible with the requirements for a clinical CZE-based **assay**.

L161 ANSWER 21 OF 32 MEDLINE

DUPLICATE 11

96248150 Document Number: 96248150.

**Carbohydrate-deficient transferrin** for identification of drug overdose patients at risk of an alcohol withdrawal syndrome. Koppel C; Muller C; Wrobel N. (Poison Information Center, Department of Internal Medicine, Berlin, Germany. ) JOURNAL OF TOXICOLOGY. CLINICAL TOXICOLOGY, (1996) 34 (3) 297-300. Journal code: KAN. ISSN: 0731-3810. Pub. country: United States.

Language:

English.

AB BACKGROUND: Chronic alcohol abuse is frequent in patients admitted to the intensive care unit with acute drug overdose. During detoxification, an alcohol withdrawal syndrome may develop in patients with a history of chronic alcohol abuse. Withdrawal or delirium is associated with serious risks, necessitating early identification of patients at risk. Since the information obtained from the patients or their relatives on **alcohol consumption** is often unreliable, biochemical markers may be helpful. **Carbohydrate deficient transferrin** is considered a highly specific marker (reported maximum specificity 97%, sensitivity 40-85%) for identifying alcohol abuse. METHODS: In 20 patients with acute drug overdose and suspected alcohol abuse, **carbohydrate deficient transferrin** was determined by an immunoturbidimetric **assay** on admission to the intensive care unit. Eight of the patients had **carbohydrate deficient transferrin** levels above the "positive" threshold and nine in a suspicious range. A "false" negative **carbohydrate deficient transferrin** was found in three patients who were thought to have changed their drinking habits prior to hospitalization. A "positive" **carbohydrate deficient transferrin** test is assumed to be associated with ingestion of more than 60-80 g ethanol/d for a period of more than seven days.

RESULTS:

Prepared by M. Hale 308-4258

Page 49

In all patients, clonidine (30-210 micrograms/h i.v.) was started. None developed delirium. Since alcohol addiction is frequently denied, **determination of carbohydrate deficient transferrin** may be useful for its early diagnosis but the sensitivity of this parameter requires further evaluation.

L161 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2000 ACS

1995:753704 Document No. 123:309893 **Assay** for glycosylation deficiency disorders. Bean, Pamela; Terryberry, Jeff W. (Specialty Laboratories Inc., USA). U.S. US 5432059 A 19950711, 11 pp. (English). CODEN: USXXAM. APPLICATION: US 1994-222422 19940401.

AB A **method** is provided for detecting **carbohydrate-deficient** glycoproteins in samples taken from subjects with metabolic disorders, such as alc. abuse and subjects who display a syndrome of carrying abnormal levels of **carbohydrate deficient** glycoproteins. The **method** involves steps of reglycosylating with a fluorescent-conjugate deglycosylated glycoproteins in a sample of **body fluid** from a subject. A further step involves fluorometric detection of fluoresceinylated carbohydrates incorporated into truncated serum glycoproteins.

L161 ANSWER 23 OF 32 MEDLINE

DUPLICATE 12

95267122 Document Number: 95267122. Diagnostic tests for **alcohol consumption**. Conigrave K M; Saunders J B; Whitfield J B. (Centre for Drug and Alcohol Studies, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia. ) ALCOHOL AND ALCOHOLISM, (1995 Jan) 30 (1)

13-26.

Ref: 105. Journal code: AAL. ISSN: 0735-0414. Pub. country: ENGLAND: United Kingdom. Language: English.

AB A variety of laboratory tests are available to assist in the diagnosis of hazardous **alcohol consumption** and related disorders. Standard tests, such as serum gamma glutamyltransferase activity and erythrocyte mean cell volume, have limited sensitivity, particularly in detecting non-dependent hazardous consumption. Most also have poor specificity in that results are affected by common diseases and medications. Over the past 10 years a number of new laboratory tests have emerged. One of these, **carbohydrate deficient transferrin**, has high sensitivity in detecting persons with alcohol dependence, and shows promise for identification of non-dependent hazardous drinking; it is also highly specific. Others such as

measurement

of bound acetaldehyde, serum beta-hexosaminidase and the ratio of urinary serotonin metabolites offer promise in detecting recent heavy drinking. However, many issues remain unresolved. The newer markers have often been judged by contrasting their values in patients who are clearly alcohol dependent and abstainers or very light drinkers. It is now apparent that some are relatively insensitive markers of hazardous consumption. Future research needs to examine the performance of these markers among subjects with a range of alcohol intakes to fully **determine** their value in assessing drinking history. In addition, **assays** which are capable of some degree of automation need to be developed for analysing large numbers of samples.

L161 ANSWER 24 OF 32 MEDLINE

DUPLICATE 13

94177716 Document Number: 94177716. Two **methods** for measuring

**carbohydrate-deficient transferrin** in

Prepared by M. Hale 308-4258

Page 50

inpatient alcoholics and healthy controls compared. Anton R; Bean P.  
(Medical University of South Carolina, Charleston 29425-0742. ) CLINICAL  
CHEMISTRY, (1994 Mar) 40 (3) 364-8. Journal code: DBZ. ISSN: 0009-9147.  
Pub. country: United States. Language: English.

AB Carbohydrate-deficient transferrins (CDTs),  
naturally occurring glycosylated transferrin proteins, are  
reported to be increased in the serum of individuals who consume large  
quantities of alcohol (ethanol). We compared two methods for the  
separation and quantification of CDT, using the same alcohol-dependent  
patients and age-, gender-, and race-matched controls as sources of  
samples for both assays. There was good correlation ( $r = 0.89$ )  
between the microcolumn anion-exchange chromatography/RIA (MAEC/RIA)  
procedure and the isoelectric focusing, immunoblotting, and laser  
densitometry (IEF/IB/LD) procedure. Receiver operating characteristic  
analysis suggested that the IEF/IB/LD procedure would perform slightly  
better than MAEC/RIA for the overall population. However, both  
assays were much more sensitive for the detection of heavy  
alcohol consumption in men, compared with women.  
Alcohol consumption in the week prior to CDT measurement  
correlated only weakly with the concentrations measured with either  
assay.

L161 ANSWER 25 OF 32 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.

94145845 EMBASE Document No.: 1994145845. Carbohydrate-  
deficient transferrin during 3 weeks' heavy  
alcohol consumption. Salmela K.S.; Laitinen K.; Nystrom  
M.; Salaspuro M.. Research Unit of Alcohol Diseases, University of  
Helsinki, Tukholmankatu 8 F, SF-00290 Helsinki, Finland. Alcoholism:  
Clinical and Experimental Research 18/2 (228-230) 1994.  
ISSN: 0145-6008. CODEN: ACRSDM. Pub. Country: United States. Language:  
English. Summary Language: English.

AB To study the effect of controlled heavy drinking of 60 g ethanol/day for  
3 weeks on carbohydrate-deficient transferrin  
(CDT), a commercial double antibody kit (CDTect(TM)) was used. By the end  
of the third drinking week, a statistically significant increase in the  
mean CDT level was observed. When compared to AST and .gamma.-  
glutamyltransferase, CDT was a more informative marker. However, only in  
2 of the 10 volunteers did CDT exceed the upper normal level (20  
units/liter) recommended by the manufacturer. This indicates that the  
sensitivity of CDT to detect heavy drinking is lower than that previously  
reported. The higher accuracy has in general been obtained in studies  
comparing healthy controls with a low alcohol  
consumption to alcoholics with an alcohol  
consumption higher than that used in the present experiment. Our  
results suggest that it remains to be established whether CDT, although  
better than AST and .gamma.-glutamyltransferase, will provide a  
clinically useful tool in identifying heavy drinkers in populations covering a wide  
range of alcohol consumption.

L161 ANSWER 26 OF 32 MEDLINE

DUPLICATE 14

94310384 Document Number: 94310384. Serum alpha-fetoprotein and  
alcohol consumption. Christiansen M; Andersen J R;  
Torning J; Overgard O; Jensen S P; Magid E; Norgaard-Pedersen B.  
Prepared by M. Hale 308-4258

Page 51

(Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen.

SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION, (1994 May)  
54 (3) 215-20. Journal code: UCP. ISSN: 0036-5513. Pub. country:

ENGLAND:

United Kingdom. Language: English.

AB Fifty-nine persons, 23 chronic alcoholics and 36 normal healthy persons with a well described **alcohol consumption**, had the serum concentration of alpha-fetoprotein **determined** by a sensitive monoclonal immunofluorescent **assay**. A significant elevation in S-AFP was found in alcoholics, median 4.1 kIU/l as compared to 3.0 kIU/l in near-abstainers (< 12 g ethanol per day) ( $p < 0.02$ ). This difference was not explained by differences in age. S-AFP correlated positively with age ( $p = 0.01$ ). In non-alcoholics a borderline

significant

correlation with S-AFP was found with average daily **alcohol consumption** (self-reported) ( $p = 0.09$ ) and a significant correlation with the serum concentration of **carbohydrate-deficient transferrin** (S-CDT) ( $p = 0.004$ ). In 11 alcoholics 2 months of abstinence from alcohol was accompanied by a

median

reduction of 21% in S-AFP ( $p < 10^{-5}$ ). In alcoholics, but not in social drinkers, S-AFP correlated with S-ASAT ( $p = 0.004$ ). The increase of S-AFP with **alcohol consumption** may reflect reversible alcohol-induced liver affection.

L161 ANSWER 27 OF 32 MEDLINE

DUPLICATE 15

94084919 Document Number: 94084919. Semi-automatic **method** for **determination** of different isoforms of **carbohydrate-deficient transferrin**. Lof K; Koivula T; Seppa K; Fukunaga T; Sillanauke P. (Biomedical Research Center, Alko Ltd, Department of Clinical Chemistry. ) CLINICA CHIMICA ACTA, (1993 Aug 31) 217 (2) 175-86. Journal code: DCC. ISSN: 0009-8981. Pub. country: Netherlands. Language: English.

AB **Carbohydrate deficient transferrin** (CDT) has been reported to be one of the best biochemical markers of alcohol abuse. However, a need still exists for a simple and practical **method** for widespread laboratory use. A semi-automatic (SA) isoelectric focusing (IEF) **assay** for CDT (SA-IEF-CDT) by a Phast System is introduced here. Different isoforms of **transferrin** were separated by IEF on polyacrylamide gels (pI 4.0-6.5) and located by immunofixation with an anti-**transferrin** serum. The precipitation bands were stained with Coomassie Brilliant Blue and quantitated densitometrically. The present **method** gave a picture of the relative amounts of 10 different **transferrin** isoforms. The percentage of CDT with pI > or = 5.7 (representing di-, mono- and **asialotransferrin**) was calculated. For comparisons **transferrin** bands with pI > or = 5.6 (tri-, di-, mono-, and **asialotransferrin**), pI > or = 5.8 (mono- and **asialotransferrin**) and pI > or = 5.9 (**asialotransferrin**) as well as GGT, ASAT and ALAT were calculated. The **method** showed good linearity and it identified different isoforms in concentrations of < 10 mg/l of **transferrin**. The correlation of the present **method** with a commercially available **method** employing anion exchange followed by double antibody RIA (AE-RIA-CDT) was good ( $n = 38$ ,  $r = 0.924$ ). In 19/20 (95%) of healthy controls, the CDT value was below 4.4% (mean + 2 S.D.) of total

Prepared by M. Hale 308-4258

Page 52

**transferrin**, while higher values were observed in all 20 (100%) alcoholics. In conclusion, the developed semi-automatic **method** is a practical and reliable alternative for **determination** of different **transferrin** isoforms.

L161 ANSWER 28 OF 32 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.

94092699 EMBASE Document No.: 1994092699. Serum level of **carbohydrate-deficient transferrin** as a marker of alcoholic liver disease. Yamauchi M.; Hirakawa J.; Maezawa Y.; Nishikawa F.; Mizuhara Y.; Ohata M.; Nakajima H.; Toda G.. First Dept of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105, Japan. Alcohol and Alcoholism 28/SUPPL. 1 B (3-8) 1993. ISSN: 0735-0414. CODEN: ALALDD. Pub. Country: United Kingdom. Language: English. Summary Language: English.

AB Serum levels of **carbohydrate-deficient transferrin** (CDT) were assayed in 87 patients with alcoholic liver disease, 25 alcoholics without liver disease, 25 cases with viral liver disease and 37 healthy subjects, by two different **methods** (Pharmacia CDT RIA kit and Axis % CDT kit). The serum level of Pharmacia-CDT was significantly higher in the patients with alcoholic liver disease (38.9  $\pm$  2.8 U/l) compared to the normal subjects (18.9  $\pm$  0.2 U/l), alcoholics without liver disease (21.7  $\pm$  1.5 U/l) and non-alcoholic liver disease (viral liver disease) (23.4  $\pm$  1.6 U/l) (P

< 0.001). The serum level of Axis-CDT was also significantly higher in the patients with alcoholic liver disease (4.22  $\pm$  0.48%) compared to the normal subjects (0.84  $\pm$  0.14%), alcoholics without liver disease (1.14  $\pm$  0.23%) and non-alcoholic liver disease (1.84  $\pm$  0.29%) (P < 0.001).

A significant correlation was found between serum levels of CDT **determined** by the two kits ( $r = 0.718$ ,  $P < 0.001$ ). The serum level of Axis-CDT was significantly higher in patients with alcoholic hepatitis compared to the normal subjects ( $P < 0.005$ ), while the serum level of Pharmacia-CDT was not increased in the patients with alcoholic hepatitis. These results indicate that **determination** of serum CDT levels is a useful marker of alcoholic liver disease, not a marker for **alcohol consumption**. Axis-CDT is more useful than Pharmacia-CDT for assaying the serum level of CDT in patients with alcoholic liver disease.

L161 ANSWER 29 OF 32 MEDLINE

DUPLICATE 16

93371566 Document Number: 93371566. A modified **method** for the **assay** of **carbohydrate-deficient transferrin** (CDT) in serum. Stibler H; Borg S; Joustra M. (Department of Neurology, Karolinska Hospital, Stockholm, Sweden. ) ALCOHOL AND ALCOHOLISM. SUPPLEMENT, (1991) 1 451-4. Journal code: AAP. ISSN: 1358-6173. Pub. country: ENGLAND: United Kingdom. Language: English.

AB CDT has been shown to be a good marker of regular high alcohol intake. It has been measured principally by isoelectric focusing or pH-based anion exchange chromatography. The present **assay** was developed to improve the technical stability of the latter **method**. It is based on anion exchange of serum using ionic strength instead of pH followed by a **transferrin** in RIA of **isotransferrins** with  $pI > 5.7$ . Two hundred and fifty-one individuals were examined. With the exception of a new inborn error of glycoprotein metabolism, the

Prepared by M. Hale 308-4258

Page 53

sensitivity for alcohol abuse was 94% and the specificity was 98%. The values correlated with the total amount of alcohol recently consumed and normalized with a mean t1/2 of 15 days.

L161 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2000 ACS

1988:452324 Document No. 109:52324 **Transferrin** phenotype and level of **carbohydrate-deficient transferrin** in healthy individuals. Stibler, Helena; Borg, Stefan; Beckman, Gunhild (Dep. Neurol., Karolinska Hosp., Stockholm, 104 01, Swed.). Alcohol.: Clin. Exp. Res., 12(3); 450-3 (English) 1988. CODEN: ACRSDM. ISSN: 0145-6008.

AB Elevated concns. of **carbohydrate-deficient** components of **transferrin** (CDT) in serum may be used as a sensitive and specific marker of regular, high alc. consumption. When **detd.** by a new, simplified **assay**, CDT values are nearly normally distributed in low- or nonalc.-consuming control populations. The importance of **transferrin** phenotype for this normal variation was analyzed in healthy, European men and women with no or negligible alc. intake. No significant relation was found between phenotype and CDT value in this population. The 3 rare B-variants found had low CDT levels, and examn. of 1 subject, outside the study, with a rare D-variant indicated that D-variants may result in false-pos. CDT values. Moreover, women tended to have somewhat higher values than men, in whom CDT levels were weakly correlated with age. Other as yet undefined biol. factors are clearly responsible for the major part of the nominal variation of CDT values in nonalcoholic individuals.

L161 ANSWER 31 OF 32 MEDLINE

DUPLICATE 17

89117803 Document Number: 89117803. **Carbohydrate-deficient transferrin** (CDT) in serum in women with early alcohol addiction. Stibler H; Dahlgren L; Borg S. (Department of Neurology, Karolinska Hospital, Stockholm, Sweden. ) ALCOHOL, (1988 Sep-Oct) 5 (5) 393-8. Journal code: AG9. ISSN: 0741-8329. Pub. country: United States.

Language:

English.

AB **Carbohydrate-deficient transferrin** (CDT) in serum was **determined** by micro anion exchange chromatography and a **transferrin** radioimmune **assay** in 58 consecutive women treated for early alcohol dependence compared, with 62 healthy females with an **alcohol consumption** of 0-15 g of ethanol/day. The upper normal CDT level was 74 mg/l. CDT was elevated above this value in 83% of the alcoholic women with an intake of 60 g of ethanol/day or more for at least 7 days within the preceding two weeks. CDT values were significantly positively correlated with daily **alcohol consumption** but not with GT, ASAT, ALAT or MCV. During abstinence CDT level declined exponentially with a half-life of 14 +/- 3 days. The results indicated that CDT may be as sensitive and specific a marker in women with early alcohol addiction as in previously studied male alcoholics. The amount of alcohol consumed appeared to be more important than sex or liver function. **Determination** of CDT may thus offer a means for early objective diagnosis and adequate treatment also of women in early stages of **alcoholism**.

L161 ANSWER 32 OF 32 MEDLINE

DUPLICATE 18

87097874 Document Number: 87097874. Micro anion exchange chromatography of **carbohydrate-deficient transferrin** in serum in  
Prepared by M. Hale 308-4258

Page 54

relation to alcohol consumption (Swedish Patent 8400587-5). Stibler H; Borg S; Joustra M. ALCOHOLISM, CLINICAL AND EXPERIMENTAL RESEARCH, (1986 Oct) 10 (5) 535-44. Journal code: 35X.

ISSN:

0145-6008. Pub. country: United States. Language: English.

AB A new simplified and rapid **method** for detection and quantitation of "**carbohydrate-deficient transferrin**" in serum is described. The **method** is based on isocratic anion exchange chromatography of **isotransferrins** in disposable microcolumns followed by a double antibody **transferrin** radioimmune **assay**. This technique, which separates all **transferrin** components isoelectric above pH 5.65, showed a very good reproducibility and accuracy with a coefficient of variation between 5 and 9%. 77 alcoholic patients could be clearly separated from 80

healthy

"normal consumers" and 33 total abstainers with a specificity of 100% and a sensitivity of 91%. The values were significantly correlated to the amount of alcohol consumed during the latest month, and declined in abstaining alcoholics with a mean biological half-life of 17 days. Elevated levels occasionally appeared in healthy individuals after daily consumption of 60 g of ethanol during a 10-day period. In a sample of 187 patients with nonalcohol-related conditions only 2% false-positive values were found. This **method** is suggested as a potential tool for detecting and monitoring alcohol abuse.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	304.21	308.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.57	-10.57

STN INTERNATIONAL LOGOFF AT 10:49:32 ON 13 SEP 2000